|
Sinopharm Group Co. Ltd. is a pharmaceutical distribution and manufacturing company established in 2003. The group operates a full supply chain ecosystem centered on the distribution of drugs and medical devices, extending into pharmaceutical manufacturing, chemical reagents, medical services, and industrial-finance integration. Its business segments include drug distribution, device distribution, and the operation of retail pharmacy networks under the Guoda Pharmacy and SPS+ brands. The company serves hospitals, pharmacies, and other healthcare institutions across China, leveraging a nationwide distribution network and logistics infrastructure. Notable subsidiaries include Sinopharm Shares, Sinopharm Yizhi, Sinopharm Xingsha, and Sinopharm Digital Technology. The company maintains strategic partnerships with major pharmaceutical manufacturers such as Pfizer, Merck, AstraZeneca, Hengrui Medicine, and Innovent Biologics to facilitate the commercialization and distribution of their products. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Medical Distribution | Homepage sinopharmgroup.com.cn |
| Sector Healthcare | IR page ir.sinopharmgroup.com.cn/html/index.php | |
|
Tags
drug distribution, medical device distribution, pharmaceutical manufacturing, retail pharmacy, chemical reagents, medical services, supply chain management, logistics, Guoda Pharmacy, SPS+, Sinopharm Shares, Sinopharm Yizhi, Sinopharm Xingsha, Sinopharm Digital Technology, Sinopharm Southwest, Sinopharm Sichuan, Sinopharm Modern
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 52.987B |
| Market cap (USD) | $ 6.753B |
| P/E | 6.60 |
| PEG | — |
| P/BV | 0.33 |
| P/S | 0.08 |
| P/OCF | 1.84 |
| P/FCF | — |
| Dividend yield | 4.7% |
| Turnover / mcap | 0.10% |
| Returns | |
|---|---|
| ROE | 5.5% |
| ROI | 5.2% |
| ROIC | 11.6% |
| Profit margin | 1.2% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -5.7% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 57.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 5.9% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 575.168B | 584.508B | 596.57B | 552.148B | 521.051B | 456.415B | 425.273B | 344.526B | 277.717B | 258.388B | 227.069B | 200.131B | 166.866B | 135.787B | 102.225B | 69.234B |
| Net profit | 7.155B | 7.05B | 9.054B | 8.526B | 7.759B | 7.187B | 6.253B | 5.836B | 5.283B | 4.647B | 3.761B | 2.875B | 2.25B | 1.974B | 1.561B | 1.209B |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
Pursuant to the rules of the National Association of Financial Market Institutional Investors and the Shanghai Stock Exchange, Sinopharm Group Co. Ltd. (the “Company”) is required to publish the quarterly financial information of the Company and its subsidiaries (the “Group”) which consists of consolidated balance sheet, consolidated income statement and consolidated cash flow statement of the Group, and to publish the quarterly financial information of the Company which consists of balance sheet, income statement and cash flow statement of the Company. This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The board of directors of the Company is pleased to announce the unaudited financial information of the Group and of the Company for the nine months ended 30 September 2026 prepared in accordance with the PRC GAAP.
The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”
-1-
CONSOLIDATED FINANCIAL INFORMATION OF THE GROUP FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026 Consolidated Balance Sheet of the Group as at 30 September 2026 (All amounts in RMB unless otherwise stated) As at
As at
30 September 2026
31 December 2025
37,832,667,165.46 90,321.36 2,137,540,971.80 228,283,524,732.62 11,891,689,948.74 5,774,470,175.34 6,363,892,412.27 67,834,742,314.22 1,044,470,177.16 626,168,837.99 1,899,648,003.98
61,560,417,493.80 128,741.64 3,557,846,566.60 188,911,479,535.59 13,152,983,443.63 5,888,293,737.88 7,020,077,970.57 62,149,964,583.67 1,015,176,005.27 741,933,250.66 1,604,168,129.75
363,688,905,060.94
345,602,469,459.06
1,859,181,561.52 11,150,643,937.78
1,941,915,435.23 10,612,308,428.93
64,783,281.40 595,233,047.01 682,651,375.52 10,245,029,890.27 698,326,476.11 3,667,470,046.97 3,638,755,279.64 88,317,389.59 5,735,190,586.02 858,952,056.75 3,014,791,575.43 1,884,759,871.80
80,920,823.48 617,162,030.42 700,911,914.59 10,358,791,629.43 839,584,706.42 4,171,629,632.16 3,884,862,081.60 142,291,864.25 5,735,190,586.02 999,562,484.62 2,746,242,134.33 1,773,755,299.41
Total non-current assets
44,184,086,375.81
44,605,129,050.89
Total assets
407,872,991,436.75
390,207,598,509.95
Items Current assets: Cash at bank and on hand Financial assets held for trading Notes receivables Accounts receivables Accounts receivable financing Advances to suppliers Other receivables Inventories Contract assets Current portion of non-current assets Other current assets Total current assets Non-current assets: Long-term receivables Long-term equity investments Equity investments designated at fair value through other comprehensive income Other non-current financial assets Investment properties Fixed assets Construction in progress Right-of-use assets Intangible assets Development costs Goodwill Long-term prepaid expenses Deferred tax assets Other non-current assets
-2-
Consolidated Balance Sheet of the Group as at 30 September 2026 (continued) (All amounts in RMB unless otherwise stated) As at 30 September 2026
31 December 2025
Notes payables Accounts payables Advance from customers Contract liabilities Employee benefits payable Taxes payable Other payables Current portion of non-current liabilities Other current liabilities
66,824,540,659.41 33,678,389,927.08 124,449,760,135.26 19,216,143.49 6,577,196,788.05 1,705,320,312.00 2,131,800,472.31 17,132,167,087.31 1,563,219,018.89 4,601,834,285.84
59,177,495,038.43 37,620,519,606.80 112,627,898,741.96 26,774,510.12 5,984,158,007.29 1,891,720,592.48 2,712,717,602.55 19,498,552,763.43 5,827,294,469.62 1,291,709,910.95
Total current liabilities
258,683,444,829.64
246,658,841,243.63
Non-current liabilities: Long-term borrowings Bonds payables Lease liabilities Long-term payables Long-term employee benefits payable Provisions Deferred income Deferred tax liabilities Other non-current liabilities
1,573,459,083.43 2,997,756,986.95 2,317,562,461.00 24,525,629.46 93,571,518.27 53,183,582.67 364,214,411.68 532,638,816.81 1,962,097,640.80
647,907,860.13 2,997,576,599.23 2,495,091,771.75 30,724,811.46 89,074,000.00 62,665,087.03 341,240,286.76 565,222,611.79 1,970,561,334.76
Total non-current liabilities
9,919,010,131.07
9,200,064,362.91
268,602,454,960.71
255,858,905,606.54
Items Current liabilities: Short-term borrowings
Total liabilities
-3-
As at
Consolidated Balance Sheet of the Group as at 30 September 2026 (continued) (All amounts in RMB unless otherwise stated) Items
As at
As at
30 September 2026
31 December 2025
Owners’ equity (or shareholders’ equity): Paid-in capital (or share capital) Capital surplus Less: treasury shares held for share incentive scheme Other comprehensive income Specific reserve Surplus reserve Undistributed profits Total owners’ equity (or shareholders’ equity) attributable to equity holders of the parent Minority interest
3,120,656,191.00 20,478,949,244.29 3,838,296.96 4,484,218.33 3,834,518.12 1,787,153,157.33 61,848,169,155.24
3,120,656,191.00 20,464,117,853.73 3,838,296.96 26,647,414.25 2,576,912.13 1,787,153,157.33 58,685,647,420.90
87,239,408,187.35 52,031,128,288.69
84,082,960,652.38 50,265,732,251.03
Total owners’ equity (or shareholders’ equity)
139,270,536,476.04
134,348,692,903.41
Total liabilities and owners’ equity (or shareholders’ equity):
407,872,991,436.75
390,207,598,509.95
-4-
Consolidated Income Statement of the Group for the Nine Months Ended 30 September 2026 (All amounts in RMB unless otherwise stated) For the nine For the nine months ended months ended 30 September Items 30 September 2026 2025 1.
Total operating revenue Including: Operating revenue
427,613,390,622.63 427,613,390,622.63
431,478,679,461.46 431,478,679,461.46
Total operating cost Including: Operating cost Taxes and surcharges Selling and distribution expenses General and administrative expenses Research and development expenses Financial expenses Add: Other gains (loss shall be stated as “( )”) Investment income (loss shall be stated as “( )”)
415,965,457,402.93 397,733,828,524.02 1,026,317,551.93 11,134,761,606.28 4,689,041,968.61 151,546,456.93 1,229,961,295.16 249,282,945.08 536,279,461.42
419,666,291,482.15 400,212,858,756.46 1,034,400,291.99 11,836,015,020.83 4,854,513,658.43 172,611,662.91 1,555,892,091.53 358,429,020.43 619,486,272.51
(4,794,725.28)
(3,261,088.34)
(1,582,936,230.37)
(1,900,760,241.54)
(81,604,470.87)
(41,270,687.22)
16,710,259.17
24,387,837.51
Gains arising from changes in fair value (loss shall be stated as “( )”) Credit impairment losses (loss shall be stated as “( )”) Asset impairment losses (loss shall be stated as “( )”) Gain on disposal of assets (loss shall be stated as “( )”) 3.
Operating profit (loss shall be stated as “( )”) Add: Non-operating income Less: Non-operating expenses
10,780,870,458.85 170,445,209.38 155,671,317.62
10,869,399,092.66 141,763,153.52 129,326,462.03
Total profit (total loss shall be stated as “( )”) Less: Income tax expenses
10,795,644,350.61 2,715,622,879.56
10,881,835,784.15 2,778,064,760.65
Net profit (net loss shall be stated as “( )”)
8,080,021,471.05
8,103,771,023.50
8,080,021,471.05
8,103,771,023.50
5,313,617,051.77 2,766,404,419.28
5,306,755,602.41 2,797,015,421.09
Other comprehensive income after tax
(30,029,635.47)
22,333,921.45
Net other comprehensive income attributable to equity holders of the parent
(22,163,195.92)
11,249,119.71
Not to be reclassified subsequently to profit or loss
(6,905,612.36)
14,024,202.46
Classification according to the continuity of operation Net profit from continuing operations Attributable to: Net profit attributable to equity holders of the parent Net profit attributable to minority interest
-5-
Consolidated Income Statement of the Group for the Nine Months Ended 30 September 2026 (continued) (All amounts in RMB unless otherwise stated)
For the nine months ended 30 September 2026
For the nine months ended 30 September 2025
Change in the remeasurements of post-employment benefit obligations
(1,947,292.91)
(127,026.01)
Change in the fair value of other equity instrument investments
(4,958,319.45)
14,151,228.48
(15,257,583.56)
(2,775,082.75)
(1,576,666.88)
(131,066.55)
(13,680,916.68)
(2,644,016.20)
(7,866,439.55)
11,084,801.74
Total comprehensive income
8,049,991,835.58
8,126,104,944.95
Total comprehensive income attributable to equity holders of the parent
5,291,453,855.85
5,318,004,722.12
Total comprehensive income attributable to minority interest
2,758,537,979.73
2,808,100,222.83
Basic earnings per share
1.70
1.70
Diluted earnings per share
1.70
1.70
Items
To be reclassified subsequently to profit or loss Items under equity method that may be reclassified to profit or loss Exchange differences on translation of foreign operations Net profit/(loss) of other comprehensive income attributable to minority interest T 7.
Earnings per share:
-6-
Consolidated Cash Flow Statement of the Group for the Nine Months Ended 30 September 2026 (All amounts in RMB unless otherwise stated) For the nine months ended 30 September 2026
For the nine months ended 30 September 2025
Cash flows from operating activities: Cash received from sales of goods or rendering of services 443,306,574,542.20 Refund of taxes and surcharges 38,818,300.10 Cash received relating to other operating activities 1,874,905,362.19
432,372,267,338.70 101,245,491.57 1,889,008,154.44
Sub-total of cash inflows from operating activities
445,220,298,204.49
434,362,520,984.71
Cash paid for goods and services Cash paid to and on behalf of employees Payments of taxes and surcharges Cash paid relating to other operating activities
441,923,199,633.46 10,099,716,826.89 9,960,667,121.65 7,171,549,684.56
444,903,649,694.59 10,689,043,398.03 10,271,441,014.61 7,575,870,074.86
Sub-total of cash outflows from operating activities
469,155,133,266.56
473,440,004,182.09
Net cash flows from operating activities
(23,934,835,062.07)
(39,077,483,197.38)
Cash received from disposal of investments Cash received from returns on investments Net cash received from disposals of fixed assets, intangible assets and other long-term assets Net cash received from disposal of subsidiaries and other business units Cash received relating to other investing activities
50,599,610.83 111,471,934.36
20,075,339.56 149,122,267.78
15,170,488.96
16,428,649.71
178,043,182.92
1,216,840,430.82
Sub-total of cash inflows from investing activities
355,285,217.07
1,402,466,687.87
1,003,310,153.81 45,376,248.13
1,135,322,429.16 9,255,000.00
373,906,444.34
7,415,683.18
1,422,592,846.28
1,151,993,112.34
(1,067,307,629.21)
250,473,575.53
Items 1.
Cash flows from investing activities:
Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Net cash paid to acquire subsidiaries and other business units Cash paid relating to other investing activities Sub-total of cash outflows from investing activities Net cash flows from investing activities
-7-
Consolidated Cash Flow Statement of the Group for the Nine Months Ended 30 September 2026 (continued) (All amounts in RMB unless otherwise stated) For the nine months ended 30 September 2026
For the nine months ended 30 September 2025
8,760,000.00 79,799,565,168.70
46,734,000.00 89,232,566,302.09
Sub-total of cash inflows from financing activities
79,808,325,168.70
89,279,300,302.09
Cash repayments of borrowings Cash payments for interest expenses and distribution of dividends or profits Cash payments relating to other financing activities
70,179,488,477.56
70,663,065,741.97
4,410,454,118.47 2,505,285,493.88
4,536,092,094.52 2,539,691,060.93
Sub-total of cash outflows from financing activities
77,095,228,089.91
77,738,848,897.42
Net cash flows from financing activities
2,713,097,078.79
11,540,451,404.67
(17,744,582.53)
(4,478,915.26)
(22,306,790,195.02)
(27,291,037,132.44)
Add: Cash and cash equivalents at the beginning of the reporting period
48,796,131,751.50
54,313,359,367.31
- Cash and cash equivalents at the end of the reporting period
26,489,341,556.48
27,022,322,234.87
Items 3. Cash flows from financing activities: Cash received from capital contributions Cash received from borrowings
- Effect of foreign exchange rate changes on cash and cash equivalents
- Net increase in cash and cash equivalents
-8-
FINANCIAL INFORMATION OF THE COMPANY FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026 Balance Sheet of the Company as at 30 September 2026 (All amounts in RMB unless otherwise stated) As at
As at
Items
30 September 2026
31 December 2025
Current assets: Cash at bank and on hand Accounts receivables Accounts receivable financing Advances to suppliers Other receivables Inventories Contract assets Other current assets
7,741,993,341.01 6,096,498,965.00 7,253,195.61 14,529,861.81 21,286,212,515.86 1,496,042,732.73 5,697,742.03
24,718,334,239.66 5,268,102,169.31 104,856,718.46 14,903,634.49 22,209,292,518.98 1,349,392,403.09 108,250.00
Total current assets
36,648,228,354.05
53,664,989,933.99
Other non-current financial assets Investment properties Fixed assets Construction in progress Intangible assets Long-term prepaid expenses Deferred tax assets Other non-current assets
33,473,770,323.20 434,882,230.88 918,553,990.80 755,764,489.63 79,383,928.31 24,017,597.04 33,993,918.81 60,684,272.01 19,999,000.03
33,315,154,879.85 438,760,705.35 933,806,231.35 778,619,429.00 51,651,666.31 32,560,776.08 41,468,882.65 65,936,895.71 25,591,319.42
Total non-current assets
35,801,049,750.71
35,683,550,785.72
Total assets
72,449,278,104.76
89,348,540,719.71
Non-current assets: Long-term equity investments
-9-
Balance Sheet of the Company as at 30 September 2026 (continued) (All amounts in RMB unless otherwise stated) As at 30 September 2026
As at 31 December 2025
Current liabilities: Notes payables Accounts payables Contract liabilities Employee benefits payable Taxes payable Other payables Current portion of non-current liabilities Other current liabilities
1,105,067,612.76 2,818,148,236.17 9,158,917.79 57,956,251.17 42,669,964.58 28,610,392,686.69 3,007,324,348.17
1,928,015,501.23 2,701,991,519.56 11,702,750.23 72,347,633.74 66,925,689.24 43,010,406,195.48 3,810,556,917.65
Total current liabilities
35,650,718,017.33
51,601,946,207.13
Non-current liabilities: Bonds payables Other non-current liabilities
2,997,756,986.95 1,075,918,242.23
2,997,576,599.23 980,063,742.23
Total non-current liabilities
4,073,675,229.18
3,977,640,341.46
Total liabilities
39,724,393,246.51
55,579,586,548.59
Items
- 10 -
Balance Sheet of the Company as at 30 September 2026 (continued) (All amounts in RMB unless otherwise stated)
Items
As at 30 September 2026
As at 31 December 2025
Owners’ equity (or shareholders’ equity): Paid-in capital (or share capital) Capital surplus
3,120,656,191.00 24,460,228,580.31
3,120,656,191.00 24,460,228,580.31
Less: treasury shares held for share incentive scheme Other comprehensive income Surplus reserve Undistributed profits
3,838,296.96 5,972,707.81 1,786,969,617.66 3,354,896,058.43
3,838,296.96 6,162,697.46 1,786,969,617.66 4,398,775,381.65
Total owners’ equity (or shareholders’ equity)
32,724,884,858.25
33,768,954,171.12
Total liabilities and owners’ equity (or shareholders’ equity)
72,449,278,104.76
89,348,540,719.71
- 11 -
Income Statement of the Company for the Nine Months Ended 30 September 2026 (All amounts in RMB unless otherwise stated)
Items
For the nine
For the nine
months ended 30 September 2026
months ended 30 September 2025
Total operating revenue Including: Operating revenue
14,769,073,950.43 14,769,073,950.43
15,540,608,254.37 15,540,608,254.37
Total operating cost Including: Operating cost Taxes and surcharges Selling and distribution expenses General and administrative expenses Financial expenses Add: Other gains (loss shall be stated as “( )”) Investment income (loss shall be stated as “( )”) Credit impairment losses (loss shall be stated as “( )”) Asset impairment losses (loss shall be stated as “( )”) Gains on disposal of assets (loss shall be stated as “( )”)
14,546,188,622.24 14,153,674,781.52 32,726,167.14 237,325,742.55 247,034,914.88 (124,572,983.85) 50,692,267.96
15,325,585,530.89 14,887,271,386.20 28,660,815.39 225,653,316.90 246,660,203.38 (62,660,190.98) 48,037,035.25
925,873,656.16
1,024,777,795.92
(15,384,356.57)
(11,938,785.85)
(3,479,745.83)
(1,003,740.04)
(353,164.90)
(138,003.76)
Operating profit (loss shall be stated as “( )”) Add: Non-operating income Less: Non-operating expenses
1,180,233,985.01 106,223.96 4,081,131.51
1,274,757,025.00 6,406,769.25 2,800,011.44
Total profit (total loss shall be stated as “( )”) Less: Income tax expenses
1,176,259,077.46 66,885,628.89
1,278,363,782.81 68,822,332.34
Net profit (net loss shall be stated as “( )”)
1,109,373,448.57
1,209,541,450.47
1,109,373,448.57
1,209,541,450.47
Classification according to the continuity of operation Net profit from continuing operations
- 12 -
Income Statement of the Company for the Nine Months Ended 30 September 2026 (continued) (All amounts in RMB unless otherwise stated)
For the nine
For the nine
months ended
months ended
30 September 2026
30 September 2025
Other comprehensive income after tax
(189,989.65)
281,807.87
To be reclassified subsequently to profit or loss
(189,989.65)
281,807.87
(189,989.65)
281,807.87
1,109,183,458.92
1,209,823,258.34
Items 6.
Items under equity method that may be reclassified to profit or loss
Total comprehensive income
- 13 -
Cash Flow Statement of the Company for the Nine Months Ended 30 September 2026 (All amounts in RMB unless otherwise stated) For the nine For the nine months ended months ended 30 September 2026 30 September 2025 Items 1.
Cash flows from operating activities: Cash received from sales of goods or rendering of services Cash received relating to other operating activities
15,685,372,255.59 703,794,029.00
16,063,294,357.09 581,416,884.33
Sub-total of cash inflows from operating activities
16,389,166,284.59
16,644,711,241.42
Cash paid for goods and services Cash paid to and on behalf of employees Payments of taxes and surcharges Cash paid relating to other operating activities
16,414,941,086.21 210,534,336.10 275,627,933.13 972,646,360.33
17,087,455,511.26 207,933,040.24 241,474,333.57 840,634,284.50
Sub-total of cash outflows from operating activities
17,873,749,715.77
18,377,497,169.57
Net cash flows from operating activities
(1,484,583,431.18)
(1,732,785,928.15)
16,360,698.12 959,989,177.75
7,429,172.32 808,980,815.88
148,380.00
3,172.31
96,029,200.00 1,487,473,578.75
2,295,869,896.24
2,560,001,034.62
3,112,283,056.75
Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Cash paid relating to other investing activities
43,032,973.11 30,891,415.00 433,850,000.00
35,198,441.40 133,915,447.87
Sub-total of cash outflows from investing activities
507,774,388.11
169,113,889.27
2,052,226,646.51
2,943,169,167.48
Cash flows from investing activities: Cash received from disposal of investments Cash received from returns on investments Net cash received from disposals of fixed assets, intangible assets and other long-term assets Net cash received from disposal of subsidiaries and other business units Cash received relating to other investing activities Sub-total of cash inflows from investing activities
Net cash flows from investing activities
- 14 -
Cash Flow Statement of the Company for the Nine Months Ended 30 September 2026 (continued) (All amounts in RMB unless otherwise stated) For the nine
For the nine
months ended 30 September 2026
months ended 30 September 2025
Cash received relating to other financing activities
2,998,757,100.00 506,076,643,309.52
2,998,892,100.00 477,709,002,437.65
Sub-total of cash inflows from financing activities
509,075,400,409.52
480,707,894,537.65
Cash repayments of borrowings Cash payments for interest expenses and distribution of dividends or profits Cash payments relating to other financing activities
3,761,000,000.00
4,128,000,000.00
2,275,811,410.95 520,579,499,802.25
2,373,269,785.19 495,684,828,782.98
Sub-total of cash outflows from financing activities
526,616,311,213.20
502,186,098,568.17
Net cash flows from financing activities
(17,540,910,803.68)
(21,478,204,030.52)
(3,073,310.30)
(893,091.72)
- Net increase in cash and cash equivalents
(16,976,340,898.65)
(20,268,713,882.91)
Add: Cash and cash equivalents at the beginning of the reporting period
24,718,334,239.66
30,200,544,699.72
- Cash and cash equivalents at the end of the reporting period
7,741,993,341.01
9,931,830,816.81
Items 3. Cash flows from financing activities: Cash received from borrowings
- Effect of foreign exchange rate changes on cash and cash equivalents
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 23 October 2026
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
- 15 -
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement dated 22 October 2026 (the “Announcement”) issued by Sinopharm Group Co. Ltd. (the “Company”), in relation to the Company’s subsidiary China National Medical Device Co., Ltd. ( 中國醫療器械有限公司 ) (“CNMDC”)’s and its consolidated unaudited balance sheet, income statement and cash flow statement for the nine months ended 30 September 2026 (the “Reporting Period”). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the Reporting Period as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL CONSOLIDATED UNAUDITED FINANCIAL DATA OF CNMDC Unit: Yuan Currency: RMB
Revenue Operating profit Total comprehensive income attributable to owners of the parent company Net cash flow arising from operating activities
Total assets Total equity attributable to owners of the parent company
Reporting Period
Same period of last year
55,262,083,638.59 855,655,519.02 391,208,526.39
54,693,011,286.36 962,113,681.56 395,277,818.67
Changes of this period
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 20 October 2026 (the “Announcement”) in relation to the preliminary financial data for the nine months ended 30 September 2026 of China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company, whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of Sinopharm Accord for the nine months ended 30 September 2026 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL UNAUDITED FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD Unit: Ten Thousand Yuan Currency: RMB
Total Revenue
JanuarySeptember 2026 5,506,609.03
JanuarySeptember 2025 5,512,449.07
Operating profit
132,718.82
133,347.76
-0.47%
Total profit
131,698.99
131,765.48
-0.05%
Net profit attributable to shareholders of the listed company
95,249.00
95,711.85
-0.48%
Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses
94,477.64
92,301.90
2.36%
Basic earnings per share (Yuan)
1.56
1.56
0.00%
Weighted average return on net assets
5.03%
5.29%
Decreased by 0.26 percentage points
July-September 2025 1,832,789.23
Increase/Decrease
Total Revenue
July-September 2026 1,879,973.42
Operating profit
49,275.79
40,698.11
21.08%
Total profit
48,960.50
39,954.15
22.54%
Net profit attributable to shareholders of the listed company
34,628.65
29,121.12
18.91%
Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses
34,590.22
28,015.75
23.47%
0.57
0.48
18.75%
1.82%
1.59%
Increased by 0.23 percentage points
Basic earnings per share (Yuan) Weighted average return on net assets
2
Increase/Decrease -0.11%
2.57%
At the end of the reporting period
At the beginning of the reporting period
Increase/Decrease
Total assets
4,890,375.64
4,909,627.10
-0.39%
Equity attributable to shareholders of listed company
1,921,961.11
1,860,996.33
3.28%
Share capital (in 0’000 shares)
61,222.16
55,656.51
10.00%
Net assets per share attributable to shareholders of listed company (Yuan)
31.39
30.40
3.26%
Notes:
- The above data are prepared based on the consolidated financial statements of Sinopharm Accord.
- At the 2025 annual general meeting of Sinopharm Accord held on 21 May 2026, the “2025 Profit Distribution Proposal of Sinopharm Accord” was approved, pursuant to which a cash dividend of RMB6.16 per 10 shares (before tax) would be distributed and 1 bonus share per 10 shares would be issued to all shareholders based on a total share capital of 556,565,077 shares as at the end of 2025, resulting in an issuance of 55,656,507 bonus shares and an increase in total share capital of Sinopharm Accord to 612,221,584 shares. The equity distribution was completed for A shares on 24 June 2026 and for B shares on 26 June 2026. In accordance with the relevant requirements of the “Rules on Information Disclosure and Preparation by Companies Offering Securities to the Public No. 9 — Calculation and Disclosure of Return on Net Assets and Earnings Per Share”, Sinopharm Accord has recalculated the earnings per share for the comparative period based on the total share capital after the bonus share issuance, and has also recalculated the net assets per share attributable to shareholders of the listed company. The basic earnings per share for the same period of last year and the net assets per share attributable to shareholders of the listed company at the end of last year were adjusted from RMB1.72 and RMB33.44 to RMB1.56 and RMB30.40, respectively.
- In accordance with the relevant requirements of the “Rules on Information Disclosure and Preparation by Companies Offering Securities to the Public No. 9 — Calculation and Disclosure of Return on Net Assets and Earnings Per Share”, Sinopharm Accord has recalculated the earnings per share for the comparative period based on the total share capital after the bonus share issuance. The basic earnings per share for the period from July to September 2025 was adjusted from RMB0.52 to RMB0.48. INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION For the period from January to September 2026, Sinopharm Accord achieved a revenue of RMB55.066 billion, representing a year-on-year decrease of 0.11%; operating profit of RMB1.327 billion, representing a year-on-year decrease of 0.47%; total profit of RMB1.317 billion, representing a year-on-year decrease of 0.05%; and net profit attributable to 3
shareholders of the listed company of RMB0.952 billion, representing a year-on-year decrease of 0.48%. The weighted average return on net assets decreased by 0.26 percentage points yearon-year. In the third quarter of 2026, Sinopharm Accord achieved a revenue of RMB18.800 billion, representing a year-on-year increase of 2.57%; and net profit attributable to shareholders of the listed company of RMB0.346 billion, representing a year-on-year increase of 18.91%. The performance of each segment is as follows: For the period from January to September 2026, the distribution segment achieved a revenue of RMB40.565 billion, representing a year-on-year decrease of 0.07%; and net profit of RMB0.754 billion, representing a year-on-year increase of 4.28%. Despite the continued deepening of industry policies, Sinopharm Accord remained committed to strengthening its core business, actively expanding its market presence and adjusting its business structure. The decline in revenue continued to narrow, while profit growth regained momentum, demonstrating strong operational resilience. The retail segment (namely “Sinopharm Holding Guoda Drugstore Co., Ltd.”, hereinafter referred to as “Guoda Drugstore”) achieved a revenue of RMB15.234 billion, representing a year-on-year increase of 0.05%; and net profit of RMB27 million, representing a year-on-year increase of 105.08%. Guoda Drugstore’s sales revenue gradually stabilized. Through continuous optimization of its product mix, strategic adjustment of its store network layout, further strengthening of expense control and enhancement of operational quality, Guoda Drugstore achieved year-on-year growth in net profit during the reporting period. In 2026, the pharmaceutical industry continued to experience the deepening impact of centralized procurement and other policy measures, with industry competition shifting from scale expansion to competition in quality and efficiency. Sinopharm Accord will maintain its strategic focus, proactively adapt to changes in the industry landscape, and continue to enhance supply chain efficiency through lean operations. By actively expanding incremental markets and optimizing its product mix to cultivate new growth drivers, Sinopharm Accord will continue to break through development bottlenecks and steadily improve its operational quality and profitability. Shareholders and public investors should note that the principal unaudited financial data and indicators of Sinopharm Accord during the reporting period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the third quarter report of Sinopharm Accord may differ.
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman
Shanghai, the PRC 20 October 2026
4
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
5
References are made to (i) the notice of the EGM of Sinopharm Group Co. Ltd. (the “Company”) dated 31 August 2026 (the “Notice”); and (ii) the circular of the Company dated 31 August 2026 (the “Circular”). Terms used in this announcement shall have the same meanings as defined in the Circular unless the context otherwise requires. POLL RESULTS OF THE EGM The Board is pleased to announce that the EGM was held at 9:00 a.m. on Tuesday, 15 September 2026 at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the People’s Republic of China (the “PRC”). All resolutions proposed at the EGM were duly passed by way of poll. All Directors of the Company attended the EGM.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
The poll results in respect of the resolutions proposed at the EGM are as follows: Number of Valid Votes (%) ORDINARY RESOLUTIONS
To consider and approve (if thought fit) the re-election of Mr. Lian Wanyong as an executive Director of the seventh session of the board of the Company (the “Board”), and to authorize the Board to determine his remuneration and to authorize the chairman of the Board (the “Chairman”) or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
For
Against
2,512,576,893
34,501,960
(98.6454%)
(1.3546%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 2.
To consider and approve (if thought fit) the re-election of Mr. Yang Binghua as an executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,512,420,384
34,658,469
(98.6393%)
(1.3607%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 3.
To consider and approve (if thought fit) the re-election of Mr. Jin Bin as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,378,598,943
168,479,910
(93.3854%)
(6.6146%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.
2
To consider and approve (if thought fit) the re-election of Mr. Chen Qiyu as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,268,230,851
278,848,002
(89.0522%)
(10.9478%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 5.
To consider and approve (if thought fit) the re-election of Mr. Zu Jing as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,475,037,578
72,041,275
(97.1716%)
(2.8284%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 6.
To consider and approve (if thought fit) the re-election of Mr. Xing Yonggang as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,508,426,549
38,652,304
(98.4825%)
(1.5175%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 7.
To consider and approve (if thought fit) the re-election of Mr. Ma Yue as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,508,434,549
38,644,304
(98.4828%)
(1.5172%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.
3
To consider and approve (if thought fit) the re-election of Mr. Chen Yuqing as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,479,579,759
67,499,094
(97.3499%)
(2.6501%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 9.
To consider and approve (if thought fit) the re-election of Mr. Wen Deyong as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,464,875,880
82,202,973
(96.7727%)
(3.2273%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 10.
To consider and approve (if thought fit) the re-election of Ms. Li Ying as a non-executive Director of the seventh session of the Board, and to authorize the Board to determine her remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with her.
2,473,051,329
74,027,524
(97.0936%)
(2.9064%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 11.
To consider and approve (if thought fit) the re-election of Mr. Li Peiyu as an independent non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,517,816,794
29,262,059
(98.8512%)
(1.1488%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.
4
To consider and approve (if thought fit) the re-election of Mr. Wu Tak Lung as an independent non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,370,185,712
176,893,141
(93.0551%)
(6.9449%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 13.
To consider and approve (if thought fit) the re-election of Mr. Yu Weifeng as an independent non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,375,471,149
171,607,704
(93.2626%)
(6.7374%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 14.
To consider and approve (if thought fit) the re-election of Mr. Shi Shenghao as an independent non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,404,658,691
142,420,162
(94.4085%)
(5.5915%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 15.
To consider and approve (if thought fit) the re-election of Mr. Chen Weiru as an independent non-executive Director of the seventh session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
2,405,041,728
142,037,125
(94.4235%)
(5.5765%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. As at the date of the EGM, the total number of issued Shares of the Company and the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM was 5
3,120,656,191 Shares. There were no Shares entitling the Shareholders of the Company to attend and shall abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules, and no holders of Shares that are required under the Hong Kong Listing Rules to abstain from voting. There were no parties had stated their intention in the Circular to vote against the resolutions proposed at the EGM or to abstain from voting. Shareholders and authorized proxies holding an aggregate of 2,547,078,853 Shares, representing 81.62% of the total number of issued Shares of the Company, were present at the EGM. The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the articles of association of the Company. The EGM was chaired by Mr. Jin Bin, the chairman of the Board. In compliance with the requirements of the Hong Kong Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for the votetaking at the EGM. ELECTION OF CHAIRMAN AND VICE CHAIRMAN OF THE BOARD, AND CHAIRMEN AND MEMBERS OF THE SPECIAL COMMITTEES OF THE BOARD The Board is pleased to announce that the first meeting of the seventh session of the Board was held on 15 September 2026, and resolved to elect the chairman and vice chairman of the seventh session of the Board and chairmen and members of the special committees of the seventh session of the Board. Chairman and vice chairman of the Board The Board resolved to elect Mr. Jin Bin as the chairman of the Board and Mr. Chen Qiyu as the vice chairman of the Board. Strategy and investment committee The Board resolved and approved that the strategy and investment committee of the seventh session of the Board comprises nine Directors, namely Mr. Jin Bin, Mr. Chen Qiyu, Mr. Li Peiyu, Mr. Shi Shenghao, Mr. Chen Weiru, Mr. Lian Wanyong, Mr. Yang Binghua, Mr. Chen Yuqing and Mr. Wen Deyong. Mr. Jin Bin serves as the chairman of the strategy and investment committee. Nomination committee The Board resolved and approved that the nomination committee of the seventh session of the Board comprises six Directors, namely Mr. Jin Bin, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao, Mr. Chen Weiru and Ms. Li Ying. Mr. Jin Bin serves as the chairman of the nomination committee. Audit committee The Board resolved and approved that the audit committee of the seventh session of the Board comprises five Directors, namely Mr. Wu Tak Lung, Mr. Li Peiyu, Mr. Shi Shenghao, Mr. Zu Jing and Mr. Wen Deyong. Mr. Wu Tak Lung serves as the chairman of the audit committee. Remuneration committee The Board resolved and approved that the remuneration committee of the seventh session of the Board comprises three Directors, namely Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng. Mr. Li Peiyu serves as the chairman of the remuneration committee.
6
Legal and compliance and environmental, social and governance committee The Board resolved and approved that the legal and compliance and environmental, social and governance committee of the seventh session of the Board comprises four Directors, namely Mr. Yu Weifeng, Mr. Jin Bin, Mr. Lian Wanyong and Mr. Xing Yonggang. Mr. Yu Weifeng serves as the chairman of the legal and compliance and environmental, social and governance committee. By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 15 September 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
7
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 28 August 2026 (the “Announcement”) in relation to the 2026 interim report of China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the six months ended 30 June 2026 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD Unit: Yuan Currency: RMB The Reporting Period
Same period of last year
Increase/Decrease (%)
36,266,356,011.93
36,796,598,397.42
-1.44
Net profit attributable to shareholders of the listed company
606,203,553.40
665,907,312.44
-8.97
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses
598,874,143.25
642,861,567.03
-6.84
Net cash flow arising from operating activities
-1,518,719,454.24
15,066,690.28
-10,179.98
Basic earnings per share (Yuan/Share)
0.99
1.09
-9.17
Diluted earnings per share (Yuan/Share)
0.99
1.09
-9.17
3.21%
3.70%
Decreased by 0.49 percentage point
At the end of the Reporting Period
At the beginning of the Reporting Period
Increase/Decrease (%)
Total assets
48,170,513,881.81
49,096,270,979.03
-1.89
Net assets attributable to shareholders of listed company
18,873,322,980.86
18,609,963,275.57
1.42
Revenue
Weighted average return on net assets
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 28 August 2026
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
2
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement dated 19 August 2026 (the “Announcement”) issued by Sinopharm Group Co. Ltd. (the “Company”) in relation to the 2026 interim report of China National Medical Device Co., Ltd. (中國醫療器械有限公司)(“CNMDC”), a subsidiary of the Company. The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the six months ended 30 June 2026 (the “Reporting Period”) as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL UNAUDITED FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS OF CNMDC Unit: Yuan Currency: RMB The Reporting Period
Same period of last year
Changes of this period
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 19 August 2026 (the “Announcement”) in relation to the 2026 interim report of China National Medicines Corporation Ltd. (“SINOPHARM (CNCM LTD)”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the six months ended 30 June 2026 (the “Reporting Period”) as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) Unit: Yuan Currency: RMB At the end of the Reporting Period
At the end of last year
Changes of this period-end over the end of last year (%)
Total assets
36,039,857,574.42
36,685,023,982.59
-1.76
Net assets attributable to shareholders of the listed company
18,810,277,656.74
18,544,719,561.48
1.43
The Reporting Period
Same period of last year
Changes of this period over the same period of last year (%)
Revenue
26,728,336,667.88
25,633,950,652.46
4.27
Total profit
1,142,820,862.00
1,226,579,932.03
-6.83
Net profit attributable to shareholders of the listed company
879,769,480.08
948,547,379.33
-7.25
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses
879,770,348.32
931,500,919.48
-5.55
Net cash flow arising from operating activities
-2,634,343,548.75
-1,510,434,836.80
Not applicable
Basic earnings per share (Yuan/Share)
1.1660
1.2572
-7.25
Diluted earnings per share (Yuan/Share)
1.1660
1.2572
-7.25
Basic earnings per share after deducting non-recurring gains and losses (Yuan/Share)
1.1660
1.2346
-5.56
Weighted average return on net assets (%)
4.69
5.45
Decreased by 0.76 percentage point
Weighted average return on net assets after deducting non-recurring gains and losses (%)
4.69
5.35
Decreased by 0.66 percentage point
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman
Shanghai, the PRC 19 August 2026
As at the date of this announcement, the executive directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru. 2
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 17 August 2026 (the “Announcement”) in relation to the preliminary financial data for the six months ended 30 June 2026 (the “Reporting Period”) of China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of Sinopharm Accord for the Reporting Period as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL UNAUDITED FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD Unit: Ten Thousand Yuan Currency: RMB The Reporting Period
Same period of last year
Increase/Decrease
Total revenue
3,626,635.60
3,679,659.84
-1.44%
Operating profit
83,443.04
92,649.65
-9.94%
Total profit
82,738.49
91,811.33
-9.88%
Net profit attributable to
60,620.36
66,590.73
-8.97%
59,887.41
64,286.16
-6.84%
0.99
1.09
-9.17%
3.21%
3.70%
Decreased by 0.49
shareholders of the listed company Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses Basic earnings per share (Yuan/share) Weighted average return on net assets (%)
percentage point At the end of the Reporting Period
Total assets Equity attributable to shareholders of listed company Share capital (in 0’000 shares)
Increase/Decrease
4,817,051.39
At the beginning of the Reporting Period 4,909,627.10
1,887,332.30
1,860,996.33
1.42%
61,222.16
55,656.51
10.00%
30.83
30.40
1.41%
-1.89%
Net assets per share attributable to shareholders of listed company (Yuan/share) Notes:
- The above data is prepared based on the consolidated financial statements of Sinopharm Accord.
- At the 2025 annual general meeting of Sinopharm Accord held on 21 May 2026, the "2025 Profit Distribution Proposal of Sinopharm Accord" was approved, pursuant to which a cash dividend of RMB6.16 per 10 shares (before tax) was distributed and 1 bonus share per 10 shares was issued to all shareholders based on a total share capital of 556,565,077 shares as at the end of 2025, resulting in an issuance of 55,656,507 bonus shares and an increase in total share capital of Sinopharm Accord to 2
612,221,584 shares. The equity distribution was completed for A shares on 24 June 2026 and for B shares on 26 June 2026. In accordance with the relevant requirements of the "Rules on Information Disclosure and Preparation by Companies Offering Securities to the Public No. 9 — Calculation and Disclosure of Return on Net Assets and Earnings Per Share", Sinopharm Accord has recalculated the earnings per share for the comparative period based on the total share capital after the bonus share issuance, and has also recalculated the net assets per share attributable to shareholders of the listed company. The basic earnings per share for the same period of last year and the net assets per share attributable to shareholders of the listed company at the end of last year were adjusted from RMB1.20 and RMB33.44 to RMB1.09 and RMB30.40, respectively. INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION In the first half of 2026, Sinopharm Accord achieved a revenue of RMB36.266 billion, representing a yearon-year decrease of 1.44%; operating profit of RMB834 million, representing a year-on-year decrease of 9.94%; total profit of RMB827 million, representing a year-on-year decrease of 9.88%; and net profit attributable to shareholders of the listed company of RMB606 million, representing a year-on-year decrease of 8.97%. Accordingly, the basic earnings per share decreased by 9.17% year-on-year. Revenue and profit showed a narrowing decline compared to the first quarter, while the weighted average return on net assets decreased by 0.49 percentage point year-on-year. In the first half of 2026, the distribution segment has achieved a revenue of RMB26.539 billion, representing a year-on-year decrease of 0.91%; and a net profit of RMB460 million, representing a year-onyear decrease of 4.56%. Despite the continuing impact of deepening industry policies and short-term pressure on the segment's operations, Sinopharm Accord demonstrated strong operational resilience by expanding growth, adjusting its structure, and implementing refined management, resulting in a continued narrowing of the decline in revenue and profit. The retail segment (i.e., Sinopharm Holding Guoda Drugstore Co., Ltd., “Guoda Drugstore”) has achieved a revenue of RMB10.227 billion, representing a year-on-year decrease of 2.40%, with the decline narrowing, and a net profit of RMB13 million, representing a year-on-year decrease of 19.74%. Affected by factors such as industry policy adjustments and intensified market competition, Guoda Drugstore's sales revenue declined slightly; coupled with changes in the sales structure, the sales proportion of high-margin products decreased, leading to a reduction in gross profit and consequently a decrease in profit. In 2026, policies such as centralized procurement in the pharmaceutical industry continued to deepen, drug prices continued to decline, industry profit margins continued to narrow, and the terminal market structure accelerated its restructuring. Faced with profound industry changes and multiple uncertainties in the external environment, Sinopharm Accord has consistently adhered to its established strategy, proactively responding to challenges with high-quality development. Sinopharm Accord continues to refine and control operating costs, actively explore incremental market opportunities, optimize its product structure, strive to overcome development bottlenecks, and ensure stable operation.
3
Shareholders and public investors should note that the principal unaudited financial data and indicators of Sinopharm Accord during the Reporting Period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the interim report of Sinopharm Accord may differ. By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 17 August 2026 As at the date of this announcement, the executive directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
4
POLL RESULTS OF THE MEETINGS The board (the “Board”) of directors (the “Directors”) of Sinopharm Group Co. Ltd. (the “Company”) is pleased to announce that the 2025 annual general meeting (the “AGM”), the H shareholders’ class meeting (the “H Shareholders’ Class Meeting”) and the domestic shareholders’ class meeting (the “Domestic Shareholders’ Class Meeting”) (collectively as the “Meetings”) were held at 9:00 a.m. on Thursday, 18 June 2026, immediately after the conclusion of the AGM and immediately after the conclusion of the H Shareholders’ Class Meeting, respectively, at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the People’s Republic of China (the “PRC”). All resolutions proposed at the Meetings were duly passed by way of poll. Mr. Jin Bin, Mr. Lian Wanyong, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong, Ms. Li Ying, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru, Directors of the Company, attended the Meetings. POLL RESULTS OF THE AGM The poll results in respect of the resolutions proposed at the AGM are as follows:
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies
Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
Number of Valid Votes (%) ORDINARY RESOLUTIONS
To consider and approve the report of the Board of the Company for the year ended 31 December 2025.
For
Against
2,688,657,382
1,017,032
(99.9622%)
(0.0378%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 2.
To consider and approve the report of the supervisory committee of the Company (the “Supervisory Committee”) for the year ended 31 December 2025.
2,688,657,382
1,017,032
(99.9622%)
(0.0378%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 3.
To consider and approve the audited financial statements and the auditors’ report of the Company and its subsidiaries for the year ended 31 December 2025.
2,688,588,557
1,085,857
(99.9596%)
(0.0404%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 4.
To consider and approve the profit distribution plan and payment of the final dividend for the year ended 31 December 2025.
2,689,660,814
13,600
(99.9995%)
(0.0005%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 5.
To consider and authorize the Board to determine the remuneration of the Directors for the year ending 31 December 2026.
2,617,018,587
72,655,827
(97.2987%)
(2.7013%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 6.
To consider and authorize the Supervisory Committee to determine the remuneration of the supervisors of the Company for the year ending 31 December 2026.
2,617,101,413
72,573,001
(97.3018%)
(2.6982%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.
2
To consider and approve the appointment of Confucius International CPA Limited and Pan-China Certified Public Accountants LLP as the international auditor and the domestic auditor of the Company respectively, each to hold office until the conclusion of the next annual general meeting of the Company, and to ratify and confirm their remunerations determined by the audit committee of the Board.
2,688,191,189
1,483,225
(99.9449%)
(0.0551%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 8.
To consider and approve the delegation of power of provision of guarantees for subsidiaries of the Company to the Board with an aggregate guarantee amount of not more than 30% of the latest audited total assets of the Company over a period of 12 months and a valid period from the date of approval of such resolution at the AGM till the date of next annual general meeting; and if the above delegation is not consistent with, collides with or conflicts with the requirements under the Rules Governing the Listing of Securities (the “Hong Kong Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) or other requirements of the Hong Kong Stock Exchange, the requirements under the Hong Kong Listing Rules or other requirements of the Hong Kong Stock Exchange should be followed.
2,141,181,359
548,493,055
(79.6075%)
(20.3925%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. Number of Valid Votes (%)
SPECIAL RESOLUTIONS 9.
To consider and approve to grant a general mandate to the Board to exercise the power of the Company to allot, issue and/or deal with Domestic Shares and/or H Shares, and to sell or transfer any treasury shares (details of this resolution were set out in the notice of AGM dated 28 May 2026).
For
Against
2,073,621,757
616,052,657
(77.0956%)
(22.9044%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution. 10.
To consider and approve to grant a general mandate to the Board to exercise the power of the Company to repurchase H Shares (details of this resolution were set out in the notice of AGM dated 28 May 2026).
2,689,461,073
213,341
(99.9921%)
(0.0079%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.
3
To consider and approve the application for extending the validity period of the registration notice of the nonfinancial corporate debt financing instruments of Sinopharm Group Co. Ltd.
2,673,442,083
16,232,331
(99.3965%)
(0.6035%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.
As at the date of the AGM, the total number of issued shares of the Company and the total number of shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM was 3,120,656,191. There were no shares entitling the shareholders of the Company (the “Shareholders”) to attend and abstain from voting in favour of any resolutions proposed at the AGM as set out in Rule 13.40 of the Hong Kong Listing Rules, and no holders of shares are required under the Hong Kong Listing Rules to abstain from voting. No parties had stated their intention in the circular dated 28 May 2026 of the Company to vote against the resolutions proposed at the AGM or to abstain from voting. Shareholders and authorized proxies holding an aggregate of 2,689,674,414 shares, representing 86.19 % of the total issued shares of the Company, were present at the AGM. The holding of the AGM was in compliance with the requirements of the Company Law of the PRC and the Articles of Association of the Company. The AGM was chaired by Mr. Jin Bin, the Chairman of the Board.
POLL RESULTS OF THE H SHAREHOLDERS’ CLASS MEETING The poll results in respect of the resolution proposed at the H Shareholders’ Class Meeting are as follows: Number of Valid Votes (%)
SPECIAL RESOLUTION
To consider and approve to grant a general mandate to the Board to exercise the power of the Company to repurchase H Shares (details of this resolution were set out in the notice of H Shareholders’ Class Meeting dated 28 May 2026).
For
Against
910,492,624
213,341
(99.9766%)
(0.0234%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution. As at the date of the H Shareholders’ Class Meeting, the total number of issued H shares of the Company and the total number of H shares entitling its holders to attend and vote for or against the resolution proposed at the H Shareholders’ Class Meeting was 1,341,810,740. There were no H shares entitling the H Shareholders of the Company to attend and abstain from voting in favour of any resolution proposed at the H Shareholders’ Class Meeting as set out in Rule 13.40 of the Hong Kong Listing Rules, and no H Shareholders are required under the Hong Kong Listing Rules to abstain
4
from voting. No parties had stated their intention in the circular of the Company dated 28 May 2026 to vote against the resolution proposed at the H Shareholders’ Class Meeting or to abstain from voting. H Shareholders and authorized proxies holding an aggregate of 910,705,965 H shares, representing 67.87 % of the total issued H shares of the Company, were present at the H Shareholders’ Class Meeting. The holding of the H Shareholders’ Class Meeting was in compliance with the requirements of the Company Law of the PRC and the Articles of Association of the Company. The H Shareholders’ Class Meeting was chaired by Mr. Jin Bin, the Chairman of the Board.
POLL RESULTS OF THE DOMESTIC SHAREHOLDERS’ CLASS MEETING The poll results in respect of the resolution proposed at the Domestic Shareholders’ Class Meeting are as follows: Number of Valid Votes (%)
SPECIAL RESOLUTION
For 1.
Against
To consider and approve to grant a general mandate to the Board 0 to exercise the power of the Company to repurchase H Shares 1,778,845,451 (details of this resolution were set out in the notice of Domestic (100.0000%) (0.0000%) Shareholders’ Class Meeting dated 28 May 2026). As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.
As at the date of the Domestic Shareholders’ Class Meeting, the total number of issued domestic shares of the Company and the total number of domestic shares entitling the holders to attend and vote for or against the resolution proposed at the Domestic Shareholders’ Class Meeting was 1,778,845,451. There were no domestic shares entitling the domestic Shareholders to attend and abstain from voting in favour of any resolution proposed at the Domestic Shareholders’ Class Meeting as set out in Rule 13.40 of the Hong Kong Listing Rules, and no holders of domestic shares are required under the Hong Kong Listing Rules to abstain from voting. No parties had stated their intention in the circular of the Company dated 28 May 2026 to vote against the resolution proposed at the Domestic Shareholders’ Class Meeting or to abstain from voting. Domestic Shareholders and authorized proxies holding an aggregate of 1,778,845,451 domestic shares, representing 100% of the total issued domestic shares of the Company, were present at the Domestic Shareholders’ Class Meeting. The holding of the Domestic Shareholders’ Class Meeting was in compliance with the requirements of the Company Law of the PRC and the Articles of Association of the Company. The Domestic Shareholders’ Class Meeting was chaired by Mr. Jin Bin, the Chairman of the Board. In compliance with the requirements of the Hong Kong Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for the
5
vote-taking at the AGM, the H Shareholders’ Class Meeting and the Domestic Shareholders’ Class Meeting. PAYMENT OF THE FINAL DIVIDEND The declaration and payment of a final dividend of RMB0.69 per share (inclusive of tax) for the year ended 31 December 2025 (the “Final Dividend”) was approved at the AGM. The Final Dividend will be paid no later than 18 August 2026 to the Shareholders whose names appear on the register of members of the Company on Tuesday, 30 June 2026.
According to the Articles of Association of the Company, dividends will be denominated and declared in Renminbi. Final Dividend on domestic shares of the Company and for investors investing in the H shares of the Company through Shanghai-Hong Kong Stock Connect or Shenzhen-Hong Kong Stock Connect (the “Southbound Trading”) will be paid in Renminbi, and the Final Dividend for other H Shareholders of the Company will be paid in Hong Kong dollars. The amount of the Final Dividend payable in Hong Kong dollars shall be calculated based on the average exchange rate of Renminbi to Hong Kong dollars as announced by the People’s Bank of China for the calendar week prior to 18 June 2026 (being the date of declaration of the Final Dividend), which is HK$1.00 equivalent to RMB0.87, and the final dividend calculated based on such exchange rate shall be HK$0.79 per share (inclusive of tax). For the investors of Southbound Trading, the Company has entered into the Agreement on Distribution of Cash Dividends of H shares for Southbound Trading with China Securities Depository and Clearing Corporation Limited, pursuant to which, the Shanghai Branch and Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, each of which as a nominee of the investors of Southbound Trading, will receive all the Final Dividend distributed by the Company and distribute the Final Dividend to the relevant investors of Southbound Trading through their depositary and clearing systems. The record date and the date of distribution of cash dividends and other time arrangements for the investors of Southbound Trading will be the same as those for other H Shareholders of the Company. Pursuant to the Enterprise Income Tax Law of the PRC and its implementing regulations (the “EIT Law”), the tax rate of the enterprise income tax applicable to the income of non-resident enterprise deriving from the PRC is 10%. For this purpose, any H shares registered under the name of nonindividual enterprise, including the H shares registered under the name of HKSCC Nominees Limited, other nominees or trustees, or other organizations or entities, shall be deemed as shares held by nonresident enterprise shareholders as defined under the EIT Law. The Company will distribute the Final Dividend to non-resident enterprise shareholders subject to a deduction of 10% enterprise income tax withheld and paid by the Company on their behalf. Any resident enterprise as defined under the EIT Law which has been legally incorporated in the PRC or which has established effective administrative entities in the PRC pursuant to the laws of foreign countries (regions) and whose name appears on the register of members of H shares of the Company should deliver a legal opinion ascertaining its status as a resident enterprise furnished by
6
a qualified PRC lawyer (with the official chop of the issuing law firm affixed thereon) and relevant documents to Computershare Hong Kong Investor Services Limited in due course, if they do not wish to have the 10% enterprise income tax withheld and paid on their behalf by the Company. Pursuant to the Notice on the Issues on Levy of Individual Income Tax after the Abolishment of Guo Shui Fa [1993] No. 045 Document (the “Notice”) issued by the State Administration of Tax on 28 June 2011, the dividend to be distributed by the PRC non-foreign invested enterprises which has issued shares in Hong Kong to the overseas resident individual shareholders, is subject to the individual income tax with a tax rate of 10% in general. However, the income tax rates for respective overseas resident individual shareholders may vary depending on the relevant tax agreements between the countries of their residence and Mainland China. Thus, 10% individual income tax will be withheld from the Final Dividend payable to any individual H Shareholders whose names appear on the register of members of H shares of the Company on Tuesday, 30 June 2026, unless otherwise stated in the relevant taxation regulations, taxation agreements or the Notice. Pursuant to the Notice on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shanghai and Hong Kong Stock Markets (Cai Shui [2014] No. 81) and the Notice on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shenzhen and Hong Kong Stock Markets (Cai Shui [2016] No. 127) jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the China Securities Regulatory Commission, for dividends derived by Mainland individual investors from investing in H-share listed on the Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect or Shenzhen-Hong Kong Stock Connect, H-share companies shall withhold individual income tax at a tax rate of 20% for the investors. For Mainland securities investment funds investing in shares listed on Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect or ShenzhenHong Kong Stock Connect, the above rules also apply and individual income tax shall be levied on dividends derived therefrom. Dividends derived by Mainland enterprise investors from investing in H shares listed on Hong Kong Stock Exchange through Shanghai-Hong Kong Stock Connect or Shenzhen-Hong Kong Stock Connect shall be reported and paid by the enterprise investors themselves, and H-share companies will not withhold or pay enterprise income tax on their behalf in the distribution of dividends. The Company will have no liability in respect of any claims arising from any delay in, or inaccurate determination of the status of the Shareholders or any disputes over the mechanism of withholding.
By order of the Board of Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 18 June 2026
7
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
8
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 29 April 2026 (the “Announcement”) in relation to the report for the first quarter ended 31 March 2026 of China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the first quarter ended 31 March 2026 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD Whether it has retroactive adjustment or restatement on previous accounting data or not □ Yes No Unit: Yuan Currency: RMB The Reporting Period
Same period of last year
Changes of this period over the same period of last year (%)
17,823,409,770.31
18,293,519,382.49
-2.57%
Net profit attributable to shareholders of the listed company
287,462,500.32
327,998,492.13
-12.36%
Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses
280,052,547.60
317,427,384.37
-11.77%
Net cash flow arising from operating activities
-2,935,333,476.40
-1,817,269,997.84
-61.52%
Basic earnings per share (Yuan/Share)
0.52
0.59
-11.86%
Diluted earnings per share
0.52
0.59
-11.86%
1.53%
1.84%
Decreased by 0.31 percentage point
At the end of the Reporting Period
At the end of last year
Changes of this period over the same period of last year (%)
Total assets
49,123,776,186.09
49,096,270,979.03
0.06%
Equity attributable to shareholders of listed company
18,897,425,775.89
18,609,963,275.57
1.54%
Revenue
(Yuan/Share) Weighted average return on equity
INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION: In the first quarter of 2026, Sinopharm Accord recorded revenue of RMB17.823 billion, representing a year-onyear decrease of 2.57%; net profit attributable to shareholders of the listed company of RMB287 million, 2
representing a year-on-year decrease of 12.36%. Accordingly, the basic earnings per share recorded a year-onyear decrease of 11.86% , and the weighted average return on equity decreased by 0.31 percentage point. In the first quarter of 2026, the distribution segment recorded revenue of RMB13.356 billion, representing a year -on-year decrease of 1.72%; net profit of RMB199 million, representing a year-on-year decrease of 13.60%. The decrease was mainly attributable to the changes in industry policies and intensified market competition, which resulted in a slight decline in sales revenue. In addition, delays in downstream collections prolonged the ageing of trade receivables, resulting in a year-on-year increase in provisions for bad debts, thereby reducing profit. The retail segment (i.e. “Sinopharm Holding Guoda Drugstore Co., Ltd.” (“Guoda Drugstore”)) recorded revenue of RMB4.739 billion, representing a year-on-year decrease of 4.89%; net profit of RMB5 million, representing a year-on-year increase of 15.42%. Impacted by changes in the influenza season and market competition, the sales revenue of Guoda Drugstore declined, but the rate of decline continued to narrow. In addition, Sinopharm Accord strengthened the management of loss- making businesses and adjusted its store network structure, which led to a reduction in relatively fixed costs such as labor cost and rental expenses and contributed to an increase in net profit. In response to a complex and changing external environment, Sinopharm Accord will continue to uphold strategy-driven development, focus on high- quality development, deepen transformation and innovation, strengthen compliance and risk management, and continuously enhance operating quality and risk resilience, with a view to achieving stable and sustainable growth and laying a solid foundation for the commencement of the “15th Five- Year Plan”. By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 29 April 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
3
Pursuant to the rules of the National Association of Financial Market Institutional Investors and the Shanghai Stock Exchange, Sinopharm Group Co. Ltd. (the “Company”) is required to publish the quarterly financial information of the Company and its subsidiaries (the “Group”) which consists of consolidated balance sheet, consolidated income statement and consolidated cash flow statement of the Group, and to publish the quarterly financial information of the Company which consists of balance sheet, income statement and cash flow statement of the Company. This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The board of directors of the Company is pleased to announce the unaudited financial information of the Group and of the Company for the three months ended 31 March 2026 prepared in accordance with the PRC GAAP.
The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.” 1
CONSOLIDATED FINANCIAL INFORMATION OF THE GROUP FOR THE THREE MONTHS ENDED 31 MARCH 2026 Consolidated Balance Sheet of the Group as at 31 March 2026 (All amounts in RMB unless otherwise stated) As at
As at
31 March 2026
31 December 2025
Current assets: Cash at bank and on hand Financial assets held for trading Notes receivables Accounts receivables Accounts receivable financing Advances to suppliers Other receivables Inventories Contract assets Current portion of non-current assets Other current assets
36,366,425,714.71 119,305.08 2,579,143,527.34 220,606,317,672.04 13,581,420,420.61 5,995,786,301.08 6,939,903,535.69 66,632,693,054.90 1,049,593,008.49 737,548,275.43 1,601,614,358.71
61,560,417,493.80 128,741.64 3,557,846,566.60 188,911,479,535.59 13,152,983,443.63 5,888,293,737.88 7,020,077,970.57 62,149,964,583.67 1,015,176,005.27 741,933,250.66 1,604,168,129.75
Total current assets
356,090,565,174.08
345,602,469,459.06
1,940,413,375.71 10,918,922,652.77
1,941,915,435.23 10,612,308,428.93
118,313,015.75 604,106,822.60 706,318,106.37 10,414,855,853.86 721,116,414.08 3,969,114,021.05 3,826,377,379.03 108,783,904.18 5,734,992,550.43 948,467,850.01 2,947,989,209.65 1,784,490,677.91
80,920,823.48 617,162,030.42 700,911,914.59 10,358,791,629.43 839,584,706.42 4,171,629,632.16 3,884,862,081.60 142,291,864.25 5,735,190,586.02 999,562,484.62 2,746,242,134.33 1,773,755,299.41
Total non-current assets
44,744,261,833.40
44,605,129,050.89
Total assets
400,834,827,007.48
390,207,598,509.95
Items
Non-current assets: Long-term receivables Long-term equity investments Equity investments designated at fair value through other comprehensive income Other non-current financial assets Investment properties Fixed assets Construction in progress Right-of-use assets Intangible assets Development costs Goodwill Long-term prepaid expenses Deferred tax assets Other non-current assets
2
Consolidated Balance Sheet of the Group as at 31 March 2026(continued) (All amounts in RMB unless otherwise stated) As at
As at
31 March 2026
31 December 2025
Current liabilities: Short-term borrowings Notes payables Accounts payables Advance from customers Contract liabilities Employee benefits payable Taxes payable Other payables Current portion of non-current liabilities Other current liabilities
69,247,672,185.19 34,432,663,093.82 116,371,367,646.91 45,106,085.18 6,358,880,519.26 1,372,982,986.99 1,880,107,133.72 20,166,861,941.05 3,171,931,541.59 1,660,789,328.77
59,177,495,038.43 37,620,519,606.80 112,627,898,741.96 26,774,510.12 5,984,158,007.29 1,891,720,592.48 2,712,717,602.55 19,498,552,763.43 5,827,294,469.62 1,291,709,910.95
Total current liabilities
254,708,362,462.48
246,658,841,243.63
Non-current liabilities: Long-term borrowings Bonds payables Lease liabilities Long-term payables Long-term employee benefits payable Provisions Deferred income Deferred tax liabilities Other non-current liabilities
1,043,698,484.24 2,997,635,694.91 2,466,550,932.76 27,649,966.02 93,498,543.38 54,064,362.78 383,828,781.85 637,419,721.16 1,931,521,130.27
647,907,860.13 2,997,576,599.23 2,495,091,771.75 30,724,811.46 89,074,000.00 62,665,087.03 341,240,286.76 565,222,611.79 1,970,561,334.76
Total non-current liabilities
9,635,867,617.37
9,200,064,362.91
264,344,230,079.85
255,858,905,606.54
Items
Total liabilities
3
Consolidated Balance Sheet of the Group as at 31 March 2026 (continued) (All amounts in RMB unless otherwise stated) As at
As at
31 March 2026
31 December 2025
3,120,656,191.00 20,476,952,909.42 3,838,296.96 34,884,599.88 2,922,978.49 1,787,153,157.33 60,101,743,015.23
3,120,656,191.00 20,464,117,853.73 3,838,296.96 26,647,414.25 2,576,912.13 1,787,153,157.33 58,685,647,420.90
85,520,474,554.39 50,970,122,373.24
84,082,960,652.38 50,265,732,251.03
Total owners’ equity (or shareholders’ equity)
136,490,596,927.63
134,348,692,903.41
Total liabilities and owners’ equity (or shareholders’ equity):
400,834,827,007.48
390,207,598,509.95
Items Owners’ equity (or shareholders’ equity): Paid-in capital (or share capital) Capital surplus Less: treasury shares held for share incentive scheme Other comprehensive income Specific reserve Surplus reserve Undistributed profits Total owners’ equity (or shareholders’ equity) attributable to equity holders of the parent Minority interest
4
Consolidated Income Statement of the Group for the Three Months Ended 31 March 2026 (All amounts in RMB unless otherwise stated) For the three For the three months ended months ended 31 March 2026 Items 31 March 2025 1.
Total operating revenue Including: Operating revenue
140,765,796,066.48 140,765,796,066.48
141,661,584,829.87 141,661,584,829.87
Total operating cost Including: Operating cost Taxes and surcharges Selling and distribution expenses General and administrative expenses Research and development expenses Financial expenses Add: Other gains (loss shall be stated as “( )”) Investment income (loss shall be stated as “( )”) Profit arising from changes in fair value (loss shall be stated as “( )”) Credit impairment losses (loss shall be stated as “( )”) Asset impairment losses (loss shall be stated as “( )”)
137,253,920,027.89 131,401,491,724.98 326,432,567.79 3,602,525,821.00 1,493,061,692.01 46,588,305.33 383,819,916.78 121,947,192.84 171,266,917.56
138,048,563,427.94 131,778,859,277.36 324,279,106.94 3,840,959,654.44 1,593,864,400.95 63,255,064.90 447,345,923.35 50,612,019.32 222,206,625.34
(9,436.56)
(16,851.00)
(944,871,819.69)
(944,364,124.50)
(4,144,888.99)
(11,544,774.80)
3,484,045.86
4,608,574.03
Less: Income tax expenses
2,859,548,049.61 68,821,294.87 29,225,239.52 2,899,144,104.96 712,278,616.52
2,934,522,870.32 33,940,230.04 24,196,689.47 2,944,266,410.89 688,319,670.99
Net profit (net loss shall be stated as “( )”)
2,186,865,488.44
2,255,946,739.90
2,186,865,488.44
2,255,946,739.90
Net profit attributable to minority interest
1,413,938,139.97 772,927,348.47
1,456,971,256.91 798,975,482.99
Other comprehensive income, net of tax
19,579,179.49
(316,411.48)
Other comprehensive income attributable to equity holders of the parent, net of tax
8,237,185.63
(224,536.95)
Other comprehensive income not reclassified subsequently to profit or loss
14,859,559.83
(84,421.65)
Gain on disposal of assets (loss shall be stated as “( )”) 3.
Operating profit (loss shall be stated as “( )”) Add: Non-operating income Less: Non-operating expenses Total profit (total loss shall be stated as “( )”)
Classification according to the continuity of operation Net profit from continuing operations Attributable to: Net profit attributable to equity holders of the parent
5
Consolidated Income Statement of the Group for the Three Months Ended 31 March 2026 (continued) (All amounts in RMB unless otherwise stated) For the three months ended 31 March 2026
For the three months ended 31 March 2025
14,859,559.83
(84,421.65)
(6,622,374.20)
(140,115.30)
(736,647.47)
445,875.02
(5,885,726.73)
(585,990.32)
11,341,993.86
(91,874.53)
2,206,444,667.93
2,255,630,328.42
1,422,175,325.60
1,456,746,719.96
784,269,342.33
798,883,608.46
Basic earnings per share
0.45
0.47
Diluted earnings per share
0.45
0.47
Items Change in the fair value of other equity instrument investments Other comprehensive income reclassified subsequently to profit or loss Other comprehensive income using the equity method that may be reclassified to profit or loss Exchange differences on translation of foreign operations Other comprehensive income attributable to minority interests, net of tax T 7. Total comprehensive income Total comprehensive income attributable to equity holders of the parent Total comprehensive income attributable to minority interest 8.
Earnings per share:
6
Consolidated Cash Flow Statement of the Group for the Three Months Ended 31 March 2026 (All amounts in RMB unless otherwise stated) For the three months ended 31 March 2026
For the three months ended 31 March 2025
Cash flows from operating activities: Cash received from sales of goods or rendering of services 128,418,326,176.85 Refund of taxes and surcharges 3,395,905.91 Cash received relating to other operating activities 2,774,219,970.51
122,414,637,166.65 4,652,810.09 3,309,676,322.56
Sub-total of cash inflows from operating activities
131,195,942,053.27
125,728,966,299.30
Cash paid for goods and services Cash paid to and on behalf of employees Payments of taxes and surcharges Cash paid relating to other operating activities
153,353,848,712.31 3,828,742,709.32 3,694,339,642.03 2,486,886,686.19
151,673,886,669.24 4,211,827,855.77 3,499,903,543.15 618,840,379.46
Sub-total of cash outflows from operating activities
163,363,817,749.85
160,004,458,447.62
Net cash flows used in operating activities
(32,167,875,696.58)
(34,275,492,148.32)
Cash received from disposal of investments Cash received from returns on investments Net cash received from disposals of fixed assets, intangible assets and other long-term assets Net cash receipts from the disposal of subsidiaries and other business units Cash received relating to other investing activities
37,049,587.77 4,675,954.14
13,653,812.70 1,092,185.20
3,224,756.30
2,255,191.89
15,032,284.03
929,275,976.18
Sub-total of cash inflows from investing activities
59,982,582.24
946,277,165.97
Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Other cash payments related to investing activities
354,740,877.39 59,181,400.00
321,222,080.37 7,562,169.48
413,922,277.39
328,784,249.85
(353,939,695.15)
617,492,916.12
Items 1.
Cash flows from investing activities:
Sub-total of cash outflows from investing activities Net cash flows from investing activities
7
Consolidated Cash Flow Statement of the Group for the Three Months Ended 31 March 2026 (continued) (All amounts in RMB unless otherwise stated) For the three months ended 31 March 2026
For the three months ended 31 March 2025
6,000,000.00 30,546,279,113.56
12,750,000.00 32,575,896,874.56
Sub-total of cash inflows from financing activities
30,552,279,113.56
32,588,646,874.56
Cash repayments of borrowings Cash payments for distribution of dividends or profits and interest expenses Cash payments relating to other financing activities
21,653,442,855.28
18,051,799,184.10
452,592,916.49 628,221,792.98
584,067,465.43 1,076,365,374.60
Sub-total of cash outflows from financing activities
22,734,257,564.75
19,712,232,024.13
Net cash flows from financing activities
7,818,021,548.81
12,876,414,850.43
(7,767,870.26)
(1,081,946.18)
Items 3. Cash flows from financing activities: Cash received from capital contributions Cash received from borrowings
- Effect of foreign exchange rate changes on cash and cash equivalents
(24,711,561,713.18) (20,782,666,327.95)
- Net increase in cash and cash equivalents Add: Cash and cash equivalents at the beginning of the reporting period
48,796,131,751.50
54,313,359,367.31
- Cash and cash equivalents at the end of the reporting period
24,084,570,038.32
33,530,693,039.36
8
FINANCIAL INFORMATION OF THE COMPANY FOR THE THREE MONTHS ENDED 31 MARCH 2026 Balance Sheet of the Company as at 31 March 2026 (All amounts in RMB unless otherwise stated) As at
As at
31 March 2026
31 December 2025
Current assets: Cash at bank and on hand Accounts receivables Accounts receivable financing Advances to suppliers Other receivables Inventories Contract assets
8,961,490,073.75 5,665,740,841.41 94,533,483.91 14,641,260.70 21,954,208,384.14 1,538,163,706.79
24,718,334,239.66 5,268,102,169.31 104,856,718.46 14,903,634.49 22,209,292,518.98 1,349,392,403.09 108,250.00
Total current assets
38,228,777,750.70
53,664,989,933.99
Non-current assets: Long-term equity investments Other non-current financial assets Investment properties Fixed assets Construction in progress Intangible assets Long-term prepaid expenses Deferred tax assets Other non-current assets
33,391,022,059.37 434,882,230.88 928,086,641.14 770,500,590.07 61,835,815.33 29,087,117.71 39,041,804.97 56,886,116.04 25,056,662.05
33,315,154,879.85 438,760,705.35 933,806,231.35 778,619,429.00 51,651,666.31 32,560,776.08 41,468,882.65 65,936,895.71 25,591,319.42
Total non-current assets
35,736,399,037.56
35,683,550,785.72
Total assets
73,965,176,788.26
89,348,540,719.71
Items
9
Balance Sheet of the Company as at 31 March 2026 (continued) (All amounts in RMB unless otherwise stated) As at 31 March 2026
As at 31 December 2025
Current liabilities: Notes payables Accounts payables Contract liabilities Employee benefits payable Taxes payable Other payables Current portion of non-current liabilities
1,154,903,922.55 2,578,890,710.99 15,178,697.90 44,812,782.06 56,349,711.98 30,698,194,058.92 1,551,763,526.67
1,928,015,501.23 2,701,991,519.56 11,702,750.23 72,347,633.74 66,925,689.24 43,010,406,195.48 3,810,556,917.65
Total current liabilities
36,100,093,411.07
51,601,946,207.13
Non-current liabilities: Bonds payables Other non-current liabilities
2,997,635,694.91 980,063,742.23
2,997,576,599.23 980,063,742.23
Total non-current liabilities
3,977,699,437.14
3,977,640,341.46
Total liabilities
40,077,792,848.21
55,579,586,548.59
Paid-in capital (or share capital) Capital surplus
3,120,656,191.00 24,460,228,580.31
Less: treasury shares held for share incentive scheme Other comprehensive income Surplus reserve Undistributed profits
3,838,296.96 6,003,289.96 1,786,969,617.66 4,517,364,558.08
3,120,656,191.00 24,460,228,580.31 3,838,296.96 6,162,697.46 1,786,969,617.66 4,398,775,381.65
Total owners’ equity (or shareholders’ equity)
33,887,383,940.05
33,768,954,171.12
Total liabilities and owners’ equity (or shareholders’ equity)
73,965,176,788.26
89,348,540,719.71
Items
Owners’ equity (or shareholders’ equity):
10
Income Statement of the Company for the Three Months Ended 31 March 2026 (All amounts in RMB unless otherwise stated)
Items
For the three
For the three
months ended 31 March 2026
months ended 31 March 202
Total operating revenue Including: Operating revenue
4,810,446,591.84 4,810,446,591.84
5,213,357,504.88 5,213,357,504.88
Total operating cost Including: Operating cost Taxes and surcharges Selling and distribution expenses General and administrative expenses Financial (income) Add: Other gains (loss shall be stated as “( )”) Investment income (loss shall be stated as “( )”) Credit impairment losses (loss shall be stated as “( )”) Asset impairment losses (loss shall be stated as “( )”) Gain on disposal of assets (loss shall be stated as “( )”)
4,770,767,184.94 4,666,769,081.95 10,635,307.42 61,395,474.70 71,353,916.04 (39,386,595.17) 50,668,730.50 56,808,642.02
5,153,579,593.46 5,021,809,411.39 8,293,486.96 79,075,104.29 66,146,985.71 (21,745,394.89) 1,017,775.45 230,253,895.71
(5,513,979.88)
(9,420,934.70)
(576,930.30)
(360,944.78)
(329,242.77)
Operating profit (loss shall be stated as “( )”) Add: Non-operating income Less: Non-operating expenses
140,736,626.47 39,018.91 280,071.09
281,267,703.10 4,625,803.57 3.19
Total profit (total loss shall be stated as “( )”) Less: Income tax expenses
140,495,574.29 21,906,397.86
285,893,503.48 14,367,264.39
Net profit (net loss shall be stated as “( )”)
118,589,176.43
271,526,239.09
Net profit from continuing operations
118,589,176.43
271,526,239.09
Other comprehensive income, net of tax
(159,407.50)
409,069.89
(159,407.50)
409,069.89
(159,407.50)
409,069.89
118,429,768.93
271,935,308.98
Classification according to the continuity of operation
Other comprehensive income reclassified subsequently to profit or loss Other comprehensive income using the equity method that may be reclassified to profit or loss
Total comprehensive income
- 11 -
Cash Flow Statement of the Company for the Three Months Ended 31 March 2026 (All amounts in RMB unless otherwise stated) For the three months ended 31 March 2026 Items 1.
Cash flows from operating activities: Cash received from sales of goods or rendering of services Cash received relating to other operating activities
4,944,123,036.22 199,745,312.02
4,707,548,264.85 349,420,904.00
Sub-total of cash inflows from operating activities
5,143,868,348.24
5,056,969,168.85
Cash paid for goods and services Cash paid to and on behalf of employees Payments of taxes and surcharges Cash paid relating to other operating activities
6,203,282,875.62 91,132,314.16 69,508,554.86 177,360,637.40
6,848,356,660.01 91,559,907.66 70,632,368.54 306,214,229.12
Sub-total of cash outflows from operating activities
6,541,284,382.04
7,316,763,165.33
(1,397,416,033.80)
(2,259,793,996.48)
16,360,698.12 151,931,659.59
6,601,618.00 257,263,559.81
16,180.00 519,175,215.90
192.31 738,999,850.01
687,483,753.61
1,002,865,220.13
Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Cash paid relating to other investing activities
13,446,802.98 19,971,400.00 371,250,000.00
2,886,076.84 30,433,147.87
Sub-total of cash outflows from investing activities
404,668,202.98
33,319,224.71
Net cash flows from investing activities
282,815,550.63
969,545,995.42
Net cash flows used in operating activities 2.
For the three months ended 31 March 2025
Cash flows from investing activities: Cash received from disposal of investments Cash received from returns on investments Net cash received from disposals of fixed assets, intangible assets and other long-term assets Cash received relating to other investing activities Sub-total of cash inflows from investing activities
12
Cash Flow Statement of the Company for the Three Months Ended 31 March 2026 (continued) (All amounts in RMB unless otherwise stated)
Items
For the three
For the three
months ended 31 March 2026
months ended 31 March 2025
- Cash flows from financing activities: Cash received relating to other financing activities
160,942,114,530.64 145,221,544,720.71
Sub-total of cash inflows from financing activities
160,942,114,530.64 145,221,544,720.71 2,276,000,000.00
10,000,000.00
Cash repayments of borrowings Cash payments for distribution of dividends or profits and interest expenses Cash payments relating to other financing activities
66,972,945.59 24,878,325.73 173,282,090,894.74 159,382,078,698.70
Sub-total of cash outflows from financing activities
175,582,969,220.47 159,459,051,644.29
Net cash flows used in financing activities
(14,640,854,689.83) (14,237,506,923.58)
- Effect of foreign exchange rate changes on cash and cash equivalents
(689,575.87) (1,388,992.91) (15,756,844,165.91) (15,528,444,500.51)
- Net increase in cash and cash equivalents Add: Cash and cash equivalents at the beginning of the reporting period
24,718,334,239.66
30,200,544,699.72
- Cash and cash equivalents at the end of the reporting period
8,961,490,073.75
14,672,100,199.21
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 24 April 2026
As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
13
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement dated 23 April 2026 (the “Announcement”) issued by Sinopharm Group Co. Ltd. (the “Company”) in relation to the unaudited consolidated balance sheet, income statement and cash flow statement, and the unaudited balance sheet, income statement and cash flow statement of China National Medical Device Co., Ltd. ( 中國醫療器械有限公司 )("CNMDC"), a subsidiary of the Company, for the three months ended 31 March 2026 (the “Reporting Period”) issued by CNMDC on the websites of China Money and Shanghai Clearing House. The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of CNMDC for the three months ended 31 March 2026 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL UNAUDITED FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS Unit: Yuan Currency: RMB Changes of the Reporting Period
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 22 April 2026 (the “Announcement”) in relation to the report for the first quarter ended 31 March 2026 of China National Medicines Corporation Ltd. (“SINOPHARM (CNCM LTD)”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the first quarter ended 31 March 2026 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.” 1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) Unit: Yuan Currency: RMB The Reporting Period
Changes of this Same period of last year period over the same period of last year(%)
Revenue
13,555,320,492.97
12,713,002,292.38
6.63
Total profit
606,781,074.39
605,877,265.63
0.15
Net profit attributable to shareholders of the listed company
474,263,852.30
459,015,386.52
3.32
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses
465,082,063.18
446,230,701.31
4.22
Net cash flow arising from operating activities
-3,592,950,795.40
-1,893,175,718.90
Not applicable
Basic earnings per share (Yuan/Share)
0.6286
0.6084
3.32
Diluted earnings per share (Yuan/Share)
0.6286
0.6084
3.32
Weighted average return on equity (%)
2.52
2.64
Decreased by 0.12 percentage point
At the end of the Reporting Period
At the end of last year
Changes of this period-end over the end of last year(%)
Total assets
36,176,208,140.02
36,685,023,982.59
-1.39
Equity attributable to shareholders of listed company
19,046,139,042.12
18,544,719,561.48
2.70
Note: The Reporting Period refers to the three months ended 31 March 2026. By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 22 April 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru. 2
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 21 April 2026 (the “Announcement”) in relation to the preliminary financial data for the three monthsended 31 March 2026 of China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the three months ended 31 March 2026 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD Unit: Ten Thousand Yuan Currency: RMB The Reporting Period
Same period of last year
Increase/Decrease
1,782,340.98
1,829,351.94
-2.57%
Operating profit
37,658.69
43,913.82
-14.24%
Total profit
37,686.05
43,832.69
-14.02%
Net profit attributable to shareholders of the listed company
28,746.25
32,799.85
-12.36%
Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses
28,005.25
31,742.74
-11.77%
Basic earnings per share (Yuan/Share)
0.52
0.59
-11.86%
Weighted average return on equity
1.53%
1.84%
Decreased by 0.31 percentage point
At the end of the Reporting Period
At the end of last year
Increase/Decrease
Total assets
4,912,377.62
4,909,627.10
0.06%
Equity attributable to shareholders of listed company
1,889,742.58
1,860,996.33
1.54%
Share Capital(in 0’000 shares)
55,656.51
55,656.51
0.00%
Net assets per share attributable to shareholders of listed company (Yuan/Share)
33.95
33.44
1.53%
Revenue
Note: The above data are prepared based on the consolidated financial statements of Sinopharm Accord.
2
INFORMATION OF THE OPERATION RESULTS: In the first quarter of 2026, Sinopharm Accord recorded revenue of RMB17.823 billion, representing a year-onyear decrease of 2.57%; operating profit of RMB377 million, representing a year-on-year decrease of 14.24%; total profit of RMB377 million, representing a year-on-year decrease of 14.02%; net profit attributable to shareholders of the listed company of RMB287 million, representing a year-on-year decrease of 12.36%. Accordingly, the basic earnings per share recorded a year-on-year decrease of 11.86% , and the weighted average return on equity decreased by 0.31 percentage point. In the first quarter of 2026, the distribution segment recorded revenue of RMB13.356 billion, representing a yearon-year decrease of 1.72%; net profit of RMB199 million, representing a year-on-year decrease of 13.60%. The decrease was mainly attributable to the changes in industry policies and intensified market competition, which resulted in a slight decline in sales revenue. In addition, delays in downstream collections prolonged the ageing of trade receivables, resulting in a year-on-year increase in provisions for bad debts, thereby reducing profit. The retail segment (i.e. “Sinopharm Holding Guoda Drugstore Co., Ltd.” (“Guoda Drugstore”)) recorded revenue of RMB4.739 billion, representing a year-on-year decrease of 4.89%; net profit of RMB5 million, representing a year-on-year increase of 15.42%. Impacted by changes in the influenza season and market competition, the sales revenue of Guoda Drugstore declined, but the rate of decline continued to narrow. In addition, Sinopharm Accord strengthened the management of loss-making businesses and adjusted its store network structure, which led to a reduction in relatively fixed costs such as staff and rental expenses and contributed to an increase in net profit. In response to a complex and changing external environment, Sinopharm Accord will continue to adhere to a strategy-driven approach, focus on high-quality development, deepen transformation and innovation, strengthen compliance and risk management, and continuously enhance operating quality and risk resilience, with a view to achieving stable and sustainable growth and laying a solid foundation for the commencement of the “15th Five-Year Plan”. Shareholders and public investors should note that the principal unaudited financial data and indicators of Sinopharm Accord during the Reporting Period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the first quarter report of Sinopharm Accord may differ.
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 21 April 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru. 3
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 1 April 2026 (the “Announcement”) in relation to the annual report for the year ended 31 December 2025 (the “Reporting Period”) of China National Accord Medicines Corporation Ltd. (“Sinopharm Accord”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited accounting data and financial indicators of Sinopharm Accord for the Reporting Period as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
1
PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD Whether it has retroactive adjustment or restatement on previous accounting data or not □Yes No Unit: Yuan Currency: RMB
Item
Changes of this year compared with last year
2025
2024
Revenue
73,415,858,423.13
74,378,494,389.57
-1.29%
75,477,484,620.31
Net profit attributable to shareholders of the listed company
1,135,926,834.84
642,493,449.76
76.80%
1,599,255,755.53
Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses
1,095,695,722.62
581,177,195.97
88.53%
1,532,823,526.34
Net cash flow arising from operating activities
1,638,588,925.27
3,271,468,297.03
-49.91%
2,937,138,679.68
Basic earnings per share (Yuan/Share)
2.04
1.15
77.39%
2.87
Diluted earnings per share (Yuan/Share)
2.04
1.15
77.39%
2.87
Weighted average ROE
6.26%
3.67%
Increased by 2.59 percentage points
9.56%
Changes of this year-end
The board of directors (the “Board”) of Sinopharm Group Co. Ltd. (the “Company” or “Sinopharm”) is pleased to announce the consolidated results of the Company and its subsidiaries (the “Group”) prepared under the HKFRS Accounting Standards for the year ended 31 December 2025 (the “Reporting Period”). CHAIRMAN’S STATEMENT Dear shareholders and investors, On the occasion of the release of Sinopharm’s 2025 annual results, I, on behalf of the Board of the Company, would like to extend my sincerest gratitude to all shareholders, investors and business partners who have long trusted and supported the development of the Group, and extend my highest respect to all employees who have worked hard in all business lines and diligently performed their duties! In 2025, the pharmaceutical distribution industry entered into a critical stage of deep adjustment and transformation and breakthrough campaign. In the face of the complicated and changeable macroenvironment, the profoundly reconstructed industry landscape and the downward pressure of the market, the Board of the Company insisted on the policy of strategic guidance and overall deployment, and the management led all employees to work together with unity and determination to overcome difficulties, securing victory in the arduous operation breakthrough campaign.
The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. -1-
At the beginning of the year, the Group faced up to the severe situation of operation under pressure, and all colleagues made concerted efforts to overcome difficulties, after six months of hard work and breakthrough campaign, the operating performance has been recovering steadily since the third quarter, and the accumulated profit has increased on a year-on-year basis. At the end of the year, under the efficient promotion by the new management, the Group built on the current momentum and made further efforts, finally delivering an impressive performance record of growth against the trend – achieving a year-on-year increase of 3.94% in net profit for the whole year. Such achievement further consolidated the Group’s leading position in the domestic pharmaceutical distribution industry, highlighted its profound development foundation, strategic empowerment of the network, strong operational resilience and core market competitiveness, and laid the foundation for the successful conclusion of the Group’s development during the “14th Five-Year Plan” period. As a pharmaceutical distribution enterprise with the widest network coverage, the most complete distribution layout and the leading comprehensive strength in China, the Board of the Company has always been based on the overall situation of the industry, gained insight into the laws of the industry, and accurately fulfilled the important task and mission of pharmaceutical distribution business to ensure the security of supply chains and serve people’s livelihood and health. At present, the industry concentration is accelerating, the digital transformation is fully penetrating, the service value is continuously upgraded, and the demand for supply chain resilience is constantly increasing. The aging population, the upgrading of healthy consumption and the continuous deepening of the outflow of prescriptions have brought certain long-term growth opportunities for the industry. Meanwhile, the normalization of medical insurance cost control, the stricter industry regulation and the intensified cross-border competition have put forward higher requirements for enterprises’ comprehensive operational capabilities. In the face of the new situation, the Group firmly promoted the transformation of development mode from scale expansion to quality and efficiency, realized the organic unity of scale and efficiency as well as speed and quality, and firmly grasped the decisive opportunity of industry reform. In 2025, the Board adhered to the policy of strategic guidance and value orientation, promoted the improvement of operation quality, the innovation driving and the optimization of management. All the work was implemented and achieved results, and the development quality and operation efficiency of the Group achieved improvement. In terms of improving the operation quality, the Group strengthened value orientation and incentive constraints, promoted the cooperation and synergy among subsidiaries, improved quality and increased efficiency, and a number of core subsidiaries achieved steady profit growth, becoming an important pillar for the growth of the Group’s profitability. The Group implemented precise governance, lowered the legal person level and optimized the business structure for inefficient loss-making enterprises, eliminated inefficient assets, revitalized existing resources, focused on the development of the main business, and achieved “lean-and-heal transformation, and development without excessive burden and pressure”. The operation quality and the profitability structure have been continuously improved. The retail pharmacy segment achieved a historic strategic turnaround, becoming the biggest operation highlight of the year. The Board and the management dived deeply into the front line of the market, accurately grasped the policy orientation and the industry trends, optimized inefficient stores, and -2-
focused on the layout of high-quality stores, and the operation quality and profitability of single stores were greatly improved. The Group deepened the reform of category structure, expanded the scale of unified procurement, strengthened the implementation of the strategy of “selected products”, and simultaneously improved the inventory turnover efficiency and the profitability. The Group built a refined cost control system, rigidly reduced unreasonable costs and improved the efficiency of resource use. The Group innovated the online and offline integration mode to broaden the sources of income. The Group optimized the structure of organizations and talents to stimulate the endogenous motivation of teams. The Group cleaned up non-core assets, and improved the management efficiency. Through a series of precise and efficient comprehensive measures, within the retail pharmacy segment, the net profit of Guoda Drugstore decreased from a loss of RMB1.104 billion to a loss of RMB217 million, representing a decrease in loss of nearly RMB900 million, which provided strong support for the Group’s profit growth in 2025 and fully demonstrated the scientificity and executive force of the Group’s strategic decision-making. In terms of innovation driving, the Group regarded digitalization and intelligence as the core growth engines, broke through data barriers, restructured the business processes, and achieved full-chain collaboration, significantly improving the operation efficiency. In terms of management optimization, the management took “integrated operation” as the core starting point, broke down internal barriers, integrated all resources, released scale effect, and proactively strengthened cooperation with upstream and downstream enterprises. The management model was comprehensively upgraded to a customer-centric and full-dimensional service model. The Group continued to strengthen risk prevention and control, strictly controlled accounts receivable and inventory turnover, made every effort to revitalize inefficient and ineffective assets, and continuously optimized the operating cash flow and the asset operation quality. The Group improved the market-oriented mechanism for selecting, employing and cultivating talents, enriched the young management echelon and improved the talent development system to provide solid talent support and strategic guarantee for its high-quality development. The year 2026 marks the first year of the national “15th Five-Year” Plan, a crucial year for deepening the transformation of the pharmaceutical distribution industry, and a breakthrough campaign year for Sinopharm to stick to its main business and forge its long-term competitiveness. Standing at a new historical starting point, the Board of the Company will take a higher position and more practical measures to lead the Group to firmly anchor the main business of pharmaceutical distribution, and build the Group’s long-term and sustainable core competitiveness from five dimensions based on the advantage of national network and with efficiency improvement, transformation and upgrading as the core, so as to promote the Group to achieve further high-quality, efficient and sustainable development and continuously consolidate its leading position in the industry. Firstly, deepening the advantage of network and creating the competitiveness of a comprehensive and coordinated distribution system. The Group will comply with the trend of industry centralization and supply chain resilience upgrading, optimize the layout of national distribution and logistics network, and consolidate the basic capability of pharmaceutical distribution. The Group will deepen the integrated operation, break down barriers between regions, segments and product categories, and release scale -3-
effect and synergistic value. The Group will carry out high-quality mergers and acquisitions and consolidation around the main business, clean up non-core inefficient assets, optimize the network and the structure of assets, and strengthen the competitiveness of the network. The Group will improve the national medical emergency supply system, enhance the security guarantee capability of the supply chain, and highlight the responsibilities and commitments of leading enterprises. Secondly, exploring the potential of digital intelligence and creating efficient operation capabilities empowered by digital intelligence. The Group will closely follow the trend of digital transformation, increase investment in science and technology, break through data barriers, and build a unified intelligent supply chain platform with digitalization as the core starting point, so as to realize digital control of the whole process of procurement, warehousing, distribution and sales. The Group will use big data to optimize the allocation of resources and improve the level of demand prediction, intelligent procurement and refined inventory management. The Group will explore the launch of digital service products that are deeply integrated with business, provide integrated solutions for upstream and downstream enterprises, and promote the upgrading of the Group from “network operator of pharmaceutical and medical devices supply chains” to “digital intelligent distribution service provider”. The Group will apply new technology to improve the traceability of the full-life cycles of pharmaceutical and medical devices, so as to firmly build a bottom line of quality and compliance through digitization. Thirdly, focusing on vertical full-cycle services and horizontal one-stop services based on the highquality development of the industry. We have been exploring in the fields of innovative wholesale and retail synergic services, in-depth development of terminal market, extended services for patient management, etc. In response to the trend of high value-added services and diversified health needs, we will complete the upgrading from distribution-related services to comprehensive high value-added services, further undertake the outflow of prescriptions, empowered grassroots terminals and retail pharmacies with professional pharmaceutical services, and created a “health service node” integrating prescription circulation, medication guidance, and chronic disease management. We will focus on special fields such as tumors, rare diseases and chronic diseases, provide the upstream industry with the full chain services for commercialization, channel access and market coverage of innovative drugs, provide the downstream medical institutions with lean supply chain management services, create a full chain collaborative ecology, construct a closer “destiny community” with upstream and downstream business partners, and reshape the value ecological chain. Fourthly, focusing on lean management and creating competitiveness in fine and efficient cost control. The Group will closely follow the requirements of high-quality development of the industry, deepen lean management by taking the policy of “improving efficiency, controlling risks and strengthening quality” as the core, and realize accurate cost accounting and optimization of the whole process by relying on the “integrated” platform. We will continue to promote governance and efficiency improvement, optimize the organizational system, promote flat and agile management, and enhance the capability to respond quickly to the market. The Group will strengthen the talent team construction, and build a professional team that adapts to the national network and the transformation of digital intelligence, so as to provide talent guarantee for its sustainable development.
-4-
Fifthly, strictly abiding by the compliance bottom line and creating the standardized, stable and compliant operation capabilities. The Group will adhere to the principle of legal, compliant and honest operation as its lifeline and core competitiveness, and build a full-coverage, whole-process and penetrating compliance management system. The Group will strictly comply with laws and regulations on pharmaceutical industry regulations, anti-commercial bribery, data security and information disclosure, and embed compliance requirements into the whole chain of decision-making, operation and assessment. The Group will strengthen the implementation of compliance culture and responsibilities, and improve the internal control supervision and accountability mechanism. The Group will use digital means to realize real-time identification, early warning and disposal of compliance risks, and protect shareholders’ interests and brand reputation with stable compliance operations. Dear shareholders and investors, the pharmaceutical and healthcare industry is a strategic industry related to the national economy and people’s livelihood, and pharmaceutical distribution is a key link for the stable operation of the pharmaceutical and healthcare industry. At present, industry competition has shifted from scale competition to comprehensive strength competition of efficiency, service, innovation and compliance. Only through continuous evolution and proactive change can we ensure the solid and sustained progress of our development in the ever-changing situation. In the future, Sinopharm will maintain firm strategic focus and pragmatic operation style, spare no effort to achieve all goals and tasks in 2026. We will continuously improve our core competitiveness and market influence and the shareholder return level, and repay the trust and support of all shareholders with more excellent operation performance!
-5-
CONSOLIDATED STATEMENT OF PROFIT OR LOSS (All amounts in Renminbi thousand unless otherwise stated) FOR THE YEAR ENDED 31 DECEMBER 2025 2025
2024
4 8
575,167,877 (533,495,864)
584,507,930 (540,252,540)
5 8 8 6
41,672,013 428,514 (16,181,314) (7,837,628) (1,002,343)
44,255,390 468,622 (17,158,639) (8,413,544) (1,381,347)
(1,041,018)
(1,582,079)
16,038,224
16,188,403
99,175 (575,767)
46,923 (1,105,581)
500,245 (2,495,157)
616,970 (2,945,212)
(1,994,912)
(2,328,242)
1,230,080 2,827
1,196,478 2,918
1,232,907
1,199,396
14,799,627 (3,965,193)
14,000,899 (3,577,305)
10,834,434
10,423,594
Notes Revenue Cost of sales Gross profit Other income Selling and distribution expenses Administrative expenses Expected credit losses on financial and contract assets Losses on derecognition of financial assets measured at amortised cost and fair value through other comprehensive income Operating profit Other gains – net Other expenses
7 7
Finance income Finance costs Finance costs – net
10
Share of profits and losses of: Associates Joint ventures
Profit before tax Income tax expense
11
Profit for the year
-6-
Note Attributable to: Owners of the parent Non-controlling interests
Earnings per share attributable to ordinary equity holders of the parent (expressed in RMB per share) – Basic and diluted
12
-7-
2025
2024
7,155,094 3,679,340
7,049,683 3,373,911
10,834,434
10,423,594
2.29
2.26
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (All amounts in Renminbi thousand unless otherwise stated) FOR THE YEAR ENDED 31 DECEMBER 2025
Profit for the year Other comprehensive income/(loss): Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods: Remeasurements of post-employment benefit obligations Income tax effect
2025
2024
10,834,434
10,423,594
22,871 (5,601)
(58,966) 14,709
Remeasurements of post-employment benefit obligations, net of tax Equity investments designated at fair value through other comprehensive income: Changes in fair value Income tax effect
17,270
(44,257)
31,517 (7,879)
(4,615) 1,154
Fair value changes on financial asset, net of tax
23,638
(3,461)
Net other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods
40,908
(47,718)
Other comprehensive income that may be reclassified to profit or loss in subsequent periods: Exchange differences on translation of foreign operations Share of other comprehensive loss of associates
(7,091) (1,920)
6,648 (1,938)
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods
(9,011)
4,710
Other comprehensive income/(loss) for the year, net of tax
31,897
(43,008)
Total comprehensive income for the year
10,866,331
10,380,586
Attributable to: – Owners of the parent – Non-controlling interests
7,175,138 3,691,193
7,019,431 3,361,155
10,866,331
10,380,586
-8-
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (All amounts in Renminbi thousand unless otherwise stated) AS AT 31 DECEMBER 2025 2025
2024
6,144,487 364,101 12,084,076 8,174,953 25,357 10,586,951
7,246,238 393,033 12,386,202 8,948,873 22,530 10,145,325
80,921 617,162 94,965 2,849,179 2,543,199
50,638 675,648 111,701 2,408,387 2,995,098
43,565,351
45,383,673
63,341,334 205,622,310 1,015,176 15,242,128 129 14,366
62,352,812 200,254,553 1,218,317 16,549,885 158 5,751
12,764,286 48,796,132
12,752,736 54,313,359
Total current assets
346,795,861
347,447,571
Total assets
390,361,212
392,831,244
Note ASSETS Non-current assets Right-of-use assets Investment properties Property, plant and equipment Intangible assets Investments in joint ventures Investments in associates Equity investments designated at fair value through other comprehensive income Financial assets at fair value through profit or loss Finance lease receivables Deferred tax assets Other non-current assets Total non-current assets Current assets Inventories Trade and notes receivables Contract assets Prepayments, other receivables and other assets Financial assets at fair value through profit or loss Finance lease receivables Pledged deposits, restricted cash and bank deposits with an initial term of over three months Cash and cash equivalents
-9-
13
2025
2024
3,120,656 (3,838) 22,058,553 58,778,013
3,120,656 (3,838) 22,022,096 53,744,881
83,953,384
78,883,795
Non-controlling interests
50,206,358
47,803,507
Total equity
134,159,742
126,687,302
LIABILITIES Non-current liabilities Interest-bearing bank and other borrowings Lease liabilities Deferred tax liabilities Post-employment benefit obligations Contract liabilities Other non-current liabilities
3,645,484 2,495,092 565,223 364,902 76,084 2,329,107
8,637,231 3,259,280 638,754 412,884 54,776 2,765,429
Total non-current liabilities
9,475,892
15,768,354
63,321,164 1,498,683 150,248,418 5,984,158 24,003,793 257,070 1,412,292
62,729,048 1,760,575 151,109,247 6,828,857 26,262,003 238,557 1,447,301
Total current liabilities
246,725,578
250,375,588
Total liabilities
256,201,470
266,143,942
Total equity and liabilities
390,361,212
392,831,244
Note EQUITY Equity attributable to owners of the parent Share capital Treasury shares Other reserves Retained earnings
Current liabilities Interest-bearing bank and other borrowings Lease liabilities Trade and notes payable Contract liabilities Accruals and other payables Dividends payable Tax payable
14
- 10 -
NOTES: (All amounts in Renminbi thousand unless otherwise stated) 1
GENERAL INFORMATION Sinopharm Group Co. Ltd. (the “Company”) was established in the People’s Republic of China (the “PRC”) on 8 January 2003 as a company with limited liability under the PRC Company Law. On 6 October 2008, the Company was converted into a joint stock limited liability company under the PRC Company Law by converting its registered share capital and reserves as at 30 September 2007 with the proportion of 1:0.8699 into 1,637,037,451 shares of RMB1 each. In September 2009, the Company issued overseas-listed foreign-invested shares (“H Shares”), which were listed on the Main Board of The Stock Exchange of Hong Kong Limited (“Hong Kong Stock Exchange”) on 23 September 2009. The Company issued 204,561,102 domestic shares to China National Pharmaceutical Group Co., Ltd. (“CNPGC”) under general mandate at the issue price of RMB24.97 per consideration share on 13 December 2018. On 23 January 2020, the Company placed and issued 149,000,000 new H shares at the price of HKD27.30 per H share. The address of the Company’s registered office is 1st and 11th to 15th Floors, No.385 East Longhua Road, Huangpu District, Shanghai, the PRC. The Company and its subsidiaries (together, the “Group”) are mainly engaged in: (1) the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics, (2) the distribution of medical devices, (3) the operation of chain pharmacy stores, and (4) the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products. The ultimate holding company of the Company is CNPGC, which was established in the PRC. These financial statements are presented in Renminbi (“RMB”) and all values are rounded to the nearest thousand, unless otherwise stated. These financial statements were approved for issue by the Board of Directors on 20 March 2026.
2
BASIS OF PREPARATION OF CONSOLIDATED FINANCIAL STATEMENTS AND MATERIAL ACCOUNTING POLICY INFORMATION (a)
Basis of preparation and statement of compliance The consolidated financial statements of the Group have been prepared in accordance with HKFRS Accounting Standards (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (“HKASs”) and interpretations) as issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”). In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities (the “Listing Rules”) on the Stock Exchange of Hong Kong Limited and by the Hong Kong Companies Ordinance (“CO”). The consolidated financial statements have been prepared on a historical cost basis, except for certain financial assets which have been measured at fair value.
- 11 -
(b)
New and amendments to an HKFRS Accounting Standards that are mandatorily effective for the current year In the current year, the Group has applied the following amendments to an HKFRS Accounting Standards as issued by HKICPA for the first time, which are mandatorily effective for the Group’s annual period beginning on 1 January 2025 for the preparation of the consolidated financial statement. Amendments to HKAS 21
Lack of Exchangeability
The adoption of these new and amendments to standards does not have significant impact on the consolidated financial statements of the Group for the current year or any prior years. (c)
New and amendments to HKFRS Accounting Standards in issue but not yet effective At the date of this report, the Group has not adopted the following new and amendments to HKFRS Accounting Standards which have been issued and are not yet effective: Amendments to HKFRS 9 and HKFRS 7 Amendments to the Classification and Measurement of Financial Instruments2 Amendments to HKFRS 9 and HKFRS 7 Contracts Referencing Nature-dependent Electricity2 Amendments to HKFRS 10 and Sale or Contribution of Assets between an Investor HKAS 28 and its Associate or Joint Venture1 HKFRS 18 Presentation and Disclosure in Financial Statements3 HKFRS 19 Subsidiaries without Public Accountability: Disclosures3 Amendments to HKFRS 19 Amendments to Subsidiaries without Public Accountability:Disclosures3 Amendments to HKFRS Accounting Annual Improvements to HKFRS Accounting Standards Standards – Volume 112 Amendments to HKAS 21 Translation to a Hyperinflationary Presentation Currency3 Notes: 1 2 3
Effective for annual periods beginning on or after a date to be determined. Effective for annual periods beginning on or after 1 January 2026. Effective for annual periods beginning on or after 1 January 2027.
The directors have performed an assessment on the new standards and amendments, and have concluded on a preliminary basis that these new standards and amendments would not have a significant impact on the Group’s consolidated financial statements when they become effective, except for HKFRS 18 which will mainly impact the presentation of profit and loss statements. HKFRS 18 sets out requirements on presentation and disclosures in financial statements and will replace HKAS 1 “Presentation of Financial Statements”. HKFRS 18 introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management defined performance measures in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. Minor amendments to HKAS 7 “Statement of Cash Flows” and HKAS 33 “Earnings per Share” are also made.
- 12 -
HKFRS 18, and the consequential amendments to other HKFRS Accounting Standards, will be effective for annual periods beginning on or after 1 January 2027, with early application permitted. The application of HKFRS 18 is not expected to have material impact on the financial position of the Group but is expected to affect the presentation of the consolidated statement of profit or loss and other comprehensive income and consolidated statement of cash flows and disclosures in the future financial statements. The Group will continue to assess the impact of HKFRS 18 on the consolidated financial statements of the Group. 3
SEGMENT INFORMATION Management has determined the operating segments based on the Group’s business types, overall strategic planning, internal organisational structure and management requirements. The reportable operating segments derive their revenue primarily from the following four business types: (i)
Pharmaceutical distribution – distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics;
(ii)
Medical device distribution – distribution of medical devices, and installation and maintenance services;
(iii)
Retail pharmacy – operation of chain pharmacy stores;
(iv)
Other business – distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
Although the retail pharmacy segment does not meet the quantitative thresholds required by HKFRS 8 Operating Segments, management has concluded that this segment should be reported, as it is considered to be as a potential growth segment and is expected to continuously contribute to group revenue in the future. Segment assets are those operating assets that are employed by a segment in its operating activities. Segment assets consist primarily of right-of-use assets, investment properties, property, plant and equipment, intangible assets, investments in associates and joint ventures, inventories, receivables and operating cash. Segment liabilities are those operating liabilities that result from the operating activities of a segment. Segment liabilities do not include borrowings, deferred tax liabilities and other liabilities that are incurred for financing rather than operating purposes. Unallocated assets mainly represent deferred tax assets. Unallocated liabilities mainly represent corporate borrowings and deferred tax liabilities. Capital expenditure comprises mainly additions to right-of-use assets, investment properties, property, plant and equipment and intangible assets, including additions resulting from acquisitions through business combinations. Inter-segment revenues are conducted at prices and on terms mutually agreed upon amongst those business segments. The revenue from external parties is measured in a manner consistent with that in the consolidated statement of profit or loss.
- 13 -
(i)
For the year ended 31 December 2025 and 2024 Pharmaceutical distribution RMB’000
Medical device distribution RMB’000
Retail pharmacy RMB’000
Other business RMB’000
Eliminations RMB’000
Group RMB’000
Year ended 31 December 2025 Segment results External segment revenue Inter-segment revenue
415,312,406 20,079,197
115,182,314 355,403
37,932,797 449,976
6,740,360 2,112,566
– (22,997,142)
575,167,877 –
Revenue
435,391,603
115,537,717
38,382,773
8,852,926
(22,997,142)
575,167,877
Operating profit Other gains, net Other expenses Share of profits and losses of associates and joint ventures
11,878,259 6,875 (223,955) (33,753)
2,571,905 65,254 (70,678) 41,423
600,251 5,163 (270,197) (2,281)
884,911 21,883 (10,937) 1,227,518
102,898 – – –
16,038,224 99,175 (575,767) 1,232,907
11,627,426
2,607,904
332,936
2,123,375
102,898
16,794,539
Finance costs, net
(1,994,912)
Profit before tax Income tax expense
14,799,627 (3,965,193)
Profit for the year
10,834,434
Other segment items included in the statement of profit or loss Expected credit losses of financial and contract assets Provision/(Reversal of provision) for impairment of prepayment Write-down of inventories, net Provision for impairment of property, plant and equipment Provision for impairment of intangible assets Depreciation of property, plant and equipment Depreciation of investment properties Depreciation of right-of-use assets Amortisation of intangible assets
785,804 3,603 33,135 – 220,352 1,102,202 19,385 801,136 404,049
199,575 11,397 70,519 913 58,368 366,897 10,086 264,177 –
11,070 (127) (1,394) – 270,324 266,405 354 917,611 50,263
5,894 – (2,042) 10,937 – 36,542 886 48,867 195
– – – – – – – – –
1,002,343 14,873 100,218 11,850 549,044 1,772,046 30,711 2,031,791 454,507
Capital expenditures
1,097,865
533,737
194,018
91,678
–
1,917,298
- 14 -
Pharmaceutical distribution RMB’000
Medical device distribution RMB’000
Retail pharmacy RMB’000
Other business RMB’000
Eliminations RMB’000
Group RMB’000
Year ended 31 December 2024 Segment results External segment revenue Inter-segment revenue
424,563,607 19,801,005
117,511,994 403,143
35,383,741 597,522
7,048,588 2,057,899
– (22,859,569)
584,507,930 –
Revenue
444,364,612
117,915,137
35,981,263
9,106,487
(22,859,569)
584,507,930
Operating profit Other (losses)/gains, net Other expenses Share of profits and losses of associates and joint ventures
12,171,662 (40,683) (397,087) 21,057
2,651,632 26,829 (43,522) 31,190
323,266 (3,217) (664,972) (802)
908,665 63,994 – 1,147,951
133,178 – – –
16,188,403 46,923 (1,105,581) 1,199,396
11,754,949
2,666,129
(345,725)
2,120,610
133,178
16,329,141
Finance costs, net
(2,328,242)
Profit before tax Income tax expense
14,000,899 (3,577,305)
Profit for the year
10,423,594
Other segment items included in the statement of profit or loss Expected credit losses of financial and contract assets Provision/(reversal of provision) for impairment of prepayment Write-down of inventories, net Provision for impairment of intangible assets Provision for impairment of investments in associates Depreciation of property, plant and equipment Depreciation of investment properties Depreciation of right-of-use assets Amortisation of intangible assets
617,385 1,491 33,797 395,596 – 1,166,861 24,027 937,574 392,765
622,362 (4,009) 20,084 47,531 – 388,420 12,501 309,167 –
130,317 – 15,541 662,837 2,135 282,033 439 1,073,884 48,859
11,283 – 8,349 – – 38,686 1,098 57,189 189
– – – – – – – – –
1,381,347 (2,518) 77,771 1,105,964 2,135 1,876,000 38,065 2,377,814 441,813
Capital expenditures
1,409,017
685,006
249,006
117,661
–
2,460,690
- 15 -
(ii)
As at 31 December 2025 and 2024
As at 31 December 2025 Segment assets and liabilities Segment assets Segment assets include: Investments in associates and joint ventures
Pharmaceutical distribution RMB’000
Medical device distribution RMB’000
Retail pharmacy RMB’000
Other business RMB’000
Eliminations RMB’000
Group RMB’000
283,059,526
90,702,748
16,322,073
24,158,992
(26,731,306)
387,512,033
202,225
69,702
35,658
10,304,723
–
10,612,308
Unallocated assets – Deferred tax assets
2,849,179
Total assets
390,361,212
Segment liabilities
137,517,199
60,866,684
12,857,937
4,893,662
(27,465,883)
188,669,599
Unallocated liabilities – Deferred tax liabilities and borrowings
67,531,871
Total liabilities
256,201,470
As at 31 December 2024 Segment assets and liabilities Segment assets Segment assets include: Investments in associates and joint ventures
282,050,861
96,579,756
16,806,935
23,962,825
(28,977,520)
390,422,857
240,369
120,147
40,773
9,766,566
–
10,167,855
Unallocated assets – Deferred tax assets
2,408,387
Total assets
392,831,244
Segment liabilities
138,766,503
67,408,956
10,565,011
5,128,433
(27,729,994)
194,138,909
Unallocated liabilities – Deferred tax liabilities and borrowings
72,005,033
Total liabilities
266,143,942
The Group’s operations are mainly located in the PRC and substantially all non-current assets are located in the PRC. Information about major customers No revenue from a singular customer in the Reporting Period amounted to over 10% of the total revenue of the Group.
- 16 -
4
REVENUE
Revenue from contracts with customers Sales of goods (at a point in time) Logistics service income (over time) Marketing and service income (over time) Import agency income (at a point in time) Others (at a point in time) Revenue from other sources Operating lease income
2025
2024
571,383,648 1,208,121 1,821,437 54,529 475,562
580,150,510 1,296,784 2,126,971 48,632 647,394
224,580
237,639
575,167,877
584,507,930
Revenue of RMB6,828,857,000 (2024: RMB6,398,902,000) relating to carried-forward contract liabilities at the beginning of the year was recognised in the current year. 5
OTHER INCOME
Government grants
2025
2024
428,514
468,622
Government grants mainly represent subsidy income received from various government authorities as incentives to certain subsidiaries of the Group. There are no unfulfilled conditions or other contingencies attached to these grants. 6
EXPECTED CREDIT LOSSES ON FINANCIAL AND CONTRACT ASSETS
Expected credit losses of financial and contract assets, net: Trade and notes receivables Contract assets Other receivables Other non-current assets
- 17 -
2025
2024
828,855 16,239 126,608 30,641
1,312,770 10,322 62,437 (4,182)
1,002,343
1,381,347
7
OTHER GAINS, NET/OTHER EXPENSES
Other gains, net Write-back of certain liabilities Gain on disposal of subsidiaries Gain on disposal of investment in associates and a joint venture Loss on disposal of investment properties, property, plant and equipment and intangible assets Gain on disposal of right-of-use assets Foreign exchange gain/(loss), net Donation Dividend income from: Equity investments at fair value through other comprehensive income Equity investments at fair value through profit or loss Fair value losses on financial assets at fair value through profit or loss (Loss)/Gain on disposal of financial assets at fair value through profit or loss Others, net
Other expenses Provision for impairment of property, plant and equipment Provision for impairment of intangible assets (Note) (Provision)/Reversal of provision for impairment of prepayment Provision for impairment of investments in associates
2025
2024
120,807 3,095 10,767
108,082 5,509 9,400
(6,724) 24,158 929 (43,803)
(187) 74,591 (15,615) (63,462)
399 9,536
563 3,843
(9,733)
(78,326)
(6,239) (4,017)
3,591 (1,066)
99,175
46,923
(11,850) (549,044) (14,873) –
– (1,105,964) 2,518 (2,135)
(575,767)
(1,105,581)
Note: The provision for impairment of goodwill amounted to RMB459,726,000 (2024: RMB931,200,000) was included in “provision for impairment of intangible assets” under “other expenses” in the consolidated statement of profit or loss.
- 18 -
8
EXPENSES BY NATURE
Raw materials and trading merchandise consumed Employee benefit expenses (Note 9) Write-down of inventories, net Lease payments not included in the measurement of lease liabilities Depreciation of property, plant and equipment Depreciation of investment properties Depreciation of right-of-use assets Amortisation of intangible assets Auditor’s remuneration – audit services – non-audit services Advisory and consulting fees Transportation expenses Travel expenses Market development and business promotion expenses Utilities Others Total cost of sales, selling and distribution expenses, and administrative expenses
- 19 -
2025
2024
532,082,634 14,226,657 100,218
538,925,247 14,811,874 77,771
490,015 1,772,046 30,711 2,031,791 454,507
497,233 1,876,000 38,065 2,377,814 441,813
22,456 2,394 352,753 1,948,207 204,811 2,515,688 320,473 959,445
22,063 – 379,313 2,050,748 234,964 2,911,165 332,255 848,398
557,514,806
565,824,723
9
EMPLOYEE BENEFIT EXPENSES
Salaries, wages, allowances and bonuses (i) Contributions to pension plans (ii) Post-employment benefits Housing benefits (iii) Other benefits (iv)
2025
2024
10,692,374 1,467,643 2,356 625,599 1,438,685
11,278,428 1,495,458 7,238 618,954 1,411,796
14,226,657
14,811,874
Notes: (i)
Bonus was determined based on the performance of the Group as well as employees’ performance and contribution to the Group.
(ii)
As stipulated by the related regulations in the PRC, the Group makes contributions to state-sponsored retirement schemes for its employees in Mainland China. The Group has also made contributions to another retirement scheme managed by an insurance company from 2011 for its employees of the Company and certain subsidiaries. The Group’s employees make monthly contributions to the schemes at approximately 8% (2024: 8%) of the relevant income (comprising wages, salaries, allowances and bonus, and subject to maximum caps), while the Group makes contributions of 12% to 20% (2024: 12% to 20%) of such relevant income and has no further obligations for the actual payment of post-retirement benefits beyond the contributions. These retirement schemes are responsible for the entire post-retirement benefit obligations to the retired employees. Contributions of total RMB14,103,000 (31 December 2024: RMB15,021,000) were payable to the fund pension plan at the year ended 31 December 2025. There are no forfeited contributions that may be used by the Group as the employer to reduce the existing level of contributions.
(iii)
Housing benefits represent contributions to the government-supervised housing funds in Mainland China at rates ranging from 5% to 12% (2024: 5% to 12%) of the employees’ relevant income.
(iv)
Other benefits mainly represent expenses incurred for medical insurance, employee welfare, employee education and training, and for union activities.
- 20 -
10
FINANCE INCOME AND COSTS 2025
2024
Interest expense: – Interest-bearing bank and other borrowings – Net interest on net defined benefit liability – Lease liabilities
2,130,514 6,922 175,475
2,507,663 9,674 224,065
Gross interest expense Bank charges Less: Capitalised interest expense
2,312,911 195,064 (12,818)
2,741,402 211,174 (7,364)
Finance costs
2,495,157
2,945,212
Finance income: – Interest income on deposits in banks and other financial institutions – Interest income on long-term deposits
(443,204) (57,041)
(542,273) (74,697)
(500,245)
(616,970)
1,994,912
2,328,242
2025
2024
4,486,200 (521,007)
4,155,803 (578,498)
3,965,193
3,577,305
Net finance costs 11
TAXATION
Current income tax Deferred income tax
During 2025, enterprises established in the PRC are normally subject to enterprise income tax (“EIT”) at the rate of 25%, while certain subsidiaries enjoy preferential EIT at a rate of 15% as approved by the relevant tax authorities or due to their operation in designated areas with preferential EIT policies. Two of the Group’s subsidiaries are subject to Hong Kong profits tax at the rate of 16.5% (2024: 16.5%) on the estimated assessable profits arising in or derived from Hong Kong during the year, except for one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime effective from the year of assessment 2018/2019. The first HK$2,000,000 (2024: HK$2,000,000) of assessable profits of this subsidiary are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%.
- 21 -
12
EARNINGS PER SHARE The calculation of basic earnings per share amounts is based on the profit for the year attributable to ordinary equity holders of the parent and the weighted average number of ordinary shares of 3,120,656,000 (31 December 2024: 3,120,656,000) in issue excluding treasury shares at the end of the Reporting Period. The Company had no potentially dilutive ordinary shares in issue during the years ended 31 December 2025 and 2024. The calculations of basic and diluted earnings per share are based on: 2025
2024
Earnings Profit attributable to equity holders of the parent used in the basic and diluted earnings per share calculation (’000)
7,155,094
7,049,683
Shares Weighted average number of ordinary shares in issue during the year used in the basic and diluted earnings per share calculation (’000)
3,120,532
3,120,532
2.29
2.26
2025
2024
194,613,010
187,635,430
13,152,983 3,622,503
12,781,306 4,830,839
211,388,496
205,247,575
(5,766,186)
(4,993,022)
205,622,310
200,254,553
Basic and diluted earnings per share (RMB per share) 13
TRADE AND NOTES RECEIVABLES
Trade receivables Receivables held both to collect contractual cash flows and to sell Notes receivable
Less: Expected credit losses
The fair value of trade and notes receivables approximates to their carrying amount.
- 22 -
Retail sales of pharmacy stores are generally made in cash or by debit or credit cards. For all other businesses, like pharmaceutical distribution, medical device distribution and production and sales of pharmaceutical manufacturing businesses etc., sales are made on credit terms generally ranging from 30 to 210 days. The aging analysis of trade receivables, based on the invoice date and net of expected credit losses, as at the end of the reporting period, is as follows:
Within 1 year 1 to 2 years Over 2 years
2025
2024
175,264,021 9,623,396 4,024,063
169,957,622 10,185,212 2,616,934
188,911,480
182,759,768
The Group applies the simplified approach to provide for expected credit losses prescribed by HKFRS 9, which permits the use of the lifetime expected credit losses for trade and notes receivable. To measure the expected credit losses, these receivables have been grouped based on shared credit risk characteristics and the aging from billing except for individually provided, where applicable. The movements in the expected credit losses of trade and notes receivable are as follows: 2025
2024
At beginning of year Expected credit losses, net Disposal of subsidiaries Other decrease for the year Amount written off as uncollectible
4,993,022 828,855 (18,727) (27) (36,937)
3,696,174 1,312,770 (2,986) (165) (12,771)
At end of year
5,766,186
4,993,022
As at 31 December 2025, notes receivable of RMB265,288,000 (2024: RMB316,771,000) and trade receivables of RMB1,748,216,000 (2024: RMB1,555,384,000) were pledged as collateral for the Group’s bank borrowings. As at 31 December 2025, notes receivable of RMB132,598,000 (2024: RMB139,405,000) and trade receivables of RMBNil (2024: RMB202,760,000) were pledged as collateral for the Group’s notes payable. As at 31 December 2025, outstanding trade receivables of RMB28,671,075,000 (2024: RMB41,232,891,000) were derecognised under the trade receivables factoring programs without recourse. The aging of these derecognised trade receivables was basically within one year. As at 31 December 2025, the collection of such trade receivables on behalf of banks amounting to RMB3,683,008,000 (2024: RMB4,494,390,000) and the collection of such trade receivables on behalf of related parties amounting to RMB818,700,000 (2024: RMB1,266,078,000) was recorded in other payables. During the year of 2025, the losses on derecognition of trade and notes receivable was RMB1,041,018,000 (2024: RMB1,582,079,000).
- 23 -
14
TRADE AND NOTES PAYABLE
Trade payables Notes payable Notes payable under supplier finance arrangements
2025
2024
112,627,898 29,321,854 8,298,666
112,450,243 30,691,243 7,967,761
150,248,418
151,109,247
The trade and notes payable are normally settled on 90-day terms. The fair value of trade payables approximates to their carrying amount. An aging analysis of the trade and notes payable as at the end of the reporting period, based on the invoice date, is as follows:
Within 3 months Between 3 to 6 months Between 6 months to 1 year Between 1 to 2 years Over 2 years
2025
2024
98,534,981 30,022,663 11,923,340 5,878,396 3,889,038
103,692,249 26,334,770 12,135,380 6,060,875 2,885,973
150,248,418
151,109,247
The Group’s trade and notes payable are denominated in the following currencies:
RMB USD EUR NZD JPY
- 24 -
2025
2024
149,421,629 822,205 – 2,181 2,403
150,965,249 136,248 1,169 4,497 2,084
150,248,418
151,109,247
15
DIVIDENDS A final dividend for the year ended 31 December 2024 of RMB0.68 (tax inclusive) per ordinary share, based on the total share capital of the Company of 3,120,656,191 ordinary shares, amounting to RMB2,122,046,000 in total, was approved by the shareholders at the annual general meeting of the Company held on 12 June 2025. A final dividend for the year ended 31 December 2025 of RMB0.69 (tax inclusive) per ordinary share, based on the total share capital of the Company of 3,120,656,191 ordinary shares, totalling approximately RMB2,153,253,000 is to be proposed at the upcoming annual general meeting according to the resolution passed at the Board meeting held on 20 March 2026. These financial statements have not reflected this proposed dividend.
Proposed final dividend – RMB0.69 (2024: RMB0.68) per ordinary share
- 25 -
2025
2024
2,153,253
2,122,046
MANAGEMENT DISCUSSION AND ANALYSIS Review on Industrial Environment Macro-economy developed steadily and moved towards high-quality development, and industry development demonstrated resilience In 2025, China’s macro-economy withstood the internal and external complex environmental pressures, showing a trend of steady progress and innovation-driven and high-quality development. According to the data released by the National Bureau of Statistics of China, the GDP jumped to a new level of RMB140 trillion in 2025, and the annual GDP in 2025 increased by 5% year on year at constant prices. During the “14th Five-Year Plan” period, China’s economic aggregate achieved an average annual growth of 5.4%, fully demonstrating the characteristics of the strong anti-risk capability, resilience to withstand pressure and high-quality development of China’s economy. This year, China’s moderately loose monetary policy continued to play a role, providing strong support for enterprises to reduce costs and improve the financing environment. Meanwhile, the proactive fiscal policy provided unprecedented support to the social security and healthcare field. According to the data released by the Ministry of Finance, China’s healthcare expenditure increased by 5.7% year on year in 2025, effectively supporting the steady upgrading of residents’ health consumption demand. Under the background of the coordinated efforts of monetary policy and fiscal policy and the continuous deepening of the long-term trend of population aging, the medical and health industry demonstrated strong anti-cyclical resilience and vast growth potential, which was an important part of the high-quality development process of China’s economy. Optimization of VBP Policy fostered healthy competition, and deepening regulation accelerated the reshaping of the market landscape In 2025, the reform of the medical and health system continued to deepen, and the policies of volumebased procurement of drugs and high-value medical consumables and the negotiation of the catalog of medicines covered by national medical insurance were normalized and institutionalized. Although the profit margin of the traditional distribution business of the pharmaceutical distribution industry continued to be under pressure, the VBP rules focused on strengthening quality evaluation and supervision. The rules were made a series of major optimizations under the principles of “stabilizing clinical practice, ensuring quality, combating involution and preventing bid rigging”, and the policy focus was shifted from “expanding the scope and reducing prices” to “stabilizing prices and improving quality”, promoting the rational return of the prices of drugs and medical devices, and guiding the market to form a healthy competitive order. The optimization of VBP policy caused the upstream pharmaceutical companies to pay more attention to the improvement of quality, stable supply and cost control, and the downstream hospitals to pay more attention to ensuring the continuity of clinical medication habits and the diversification and stability of supply sources, thus stimulating the demand increment of personalized value services in the upstream and downstream of the industrial chain and accelerating the transformation and upgrading of pharmaceutical distribution enterprises from scale
- 26 -
growth to optimization of business structure and models. The core advantages of industry-leading pharmaceutical distribution enterprises with comprehensive terminal network coverage, efficient supply chain response and high-quality customer services were effectively highlighted. In 2025, the medical insurance funds and pharmaceutical enterprises deepened the implementation of the “direct settlement” policy and the “immediate settlement” policy with medical institutions for the amount of the VBP drugs and consumables, which had a far-reaching impact on the improvement of the overall operational efficiency and the long-term benign development of the pharmaceutical distribution industry. The National Healthcare Security Administration required that from July 2025, for sales of relevant drugs, QR codes must be scanned as required before settling with medical insurance funds, and from January 2026, all pharmaceutical institutions were required to fully collect and upload drug traceability codes. The further implementation of the medical insurance fund settlement policy has put forward higher requirements for the timely and accurate data connection and interaction capabilities and refined management capabilities of pharmaceutical distribution enterprises and medical insurance information platforms. Strong digital governance capability and traceability capability have become the barriers to competition in the industry, which will effectively drive the industry to accelerate the building of digital capacity and the extension of industrial chain services. In 2025, the normalized advancement of compliance governance in the medical field prompted pharmaceutical distribution enterprises to build a comprehensive and effective compliance risk control system, and compliant operation has become one of the core competitiveness of enterprises to resist risks and achieve high-quality development. For leading enterprises with national network layout, efficient supply chain service capability and mature compliance management level, the deepening of regulation will accelerate the reshaping of the industry landscape, create favorable conditions for highquality industry-leading enterprises to enhance market share, innovate service models and enhance the influence of the industrial chain, and lead the industry towards a more standardized and sustainable stage of high-quality development. Business Review The year 2025 was the closing year of the “14th Five-Year” Plan. In the face of industrial policies such as expansion of centralized procurement and strengthened medical insurance regulation and the complicated market competition environment, the Group, under the overall guidance by the board of directors and the management, accurately grasped the policy orientation, persisted in the principle of striving for progress while maintaining stability, focused on improving operational efficiency and managing and controlling of compliance risks, and achieved new breakthroughs in various work. In 2025, the Group’s annual revenue growth rate was higher than the overall level of the industry, and its market share continued to increase. As of the end of the Reporting Period, the Group recorded the operating income of RMB575,167.88 million, representing a year-on-year decrease of 1.6%, recorded a net profit of RMB10,834.43 million, representing a year-on-year increase of 3.94%, and recorded a profit attributable to the parent company of RMB7,155.09 million, representing a year-on-year increase of 1.50%.
- 27 -
In terms of the operational efficiency improvement, the Group anchored the scale effect and cost-led strategy to promote cost reduction and lean management. As of the end of 2025, the overall expense ratio of the Group decreased by 0.25 percentage point year on year , strongly offsetting the decline in gross profit. During the Reporting Period, the net inflow of operating cash flow was RMB14,138.21 million, representing an increase of RMB2,592.20 million compared with the same period of last year, showing remarkable results in cash flow management. The increase of accounts receivable significant narrowed and special governance on accounts receivable yielded results. The asset-liability ratio decreased by 2.12 percentage points year on year . Relying on the improvement of internal governance efficiency, the Group effectively resisted the pressure of market fluctuation, achieved a year-on-year increase of 0.02 percentage point in operating profit margin, and showed strong anti-risk capability and development resilience in its overall business, laying a solid foundation for the successful conclusion of the “14th Five-Year” Plan and the strategic layout of the “15th Five-Year” Plan. In 2025, the Group focused on the primary task of high-quality development, scientifically analyzed the market situation and competition landscape in various regions, actively expanded its market share, and accelerated the improvement of quality and efficiency with reform and innovation. During the Reporting Period, the three main business segments continued their differentiated development trend, among which, the proportion of the revenue of the pharmaceutical distribution segment was 72.79%, representing a year-on-year decrease of 0.37 percentage point; the proportion of the revenue of the medical device distribution segment was 19.32%, representing a year-on-year slight decrease of 0.09 percentage point; and the proportion of the revenue of the retail pharmacy segment was 6.42%, representing a year-on-year increase of 0.50 percentage point. Pharmaceutical Distribution: The market share has been expanded through precise implementation of strategies, steady development consolidated leading advantages In 2025, the centralized volume-based procurement of drugs continued to deepen in terms of “incremental expansion, quality improvement and efficiency enhancement”, and the implementation of policies entered a new stage of standardization, institutionalization and normalization. The centralized procurement of the eleventh batches of drugs organized by the State was successfully implemented in February 2026, and the rules were significantly optimized. The mechanism of “reporting the quantity based on the factory brand” was introduced for the first time, paying more attention to the clinical recognition, quality reputation and supply chain stability of products. The increasingly refined centralized procurement policy is pushing the industry to transform into a high-quality development path of “cost control, efficiency improvement and service-driven”. With the nationwide distribution network, efficient service guarantee capability and deep customer stickiness advantage, the pharmaceutical distribution segment of the Group demonstrated strong operational resilience. In 2025, the revenue of the pharmaceutical distribution segment recorded a revenue of RMB435,391.60 million, representing a year-on-year decrease of 2.02%, significantly narrowing the year-on-year decrease in revenue compared with 3.52% in the first half of 2025, and showing a notable sequential upward trend. During the Reporting Period, the operating profit margin of the pharmaceutical distribution business was 2.73%, which basically remained unchanged compared with the same period of last year.
- 28 -
In 2025, in terms of the pharmaceutical distribution segment, the Group took multiple measures to consolidate its market leading edge by precisely implementing strategies around expansion of market share. During the Reporting Period, the Group continued to optimize the structure of categories, stabilize the market share of centralized procurement varieties and national negotiated varieties, and enhance the coverage capacities of core areas and key terminals. Among them, the market share in the traditional advantageous regions such as Eastern China and Northern China maintained steady growth, while the market share in Southern China remained basically unchanged compared with the same period of last year. The market share of the Group’s drug distribution ranked among the top in the vast majority of provinces in China . Secondly, the Group implemented classified management for key hospital customers, optimized the resource allocation and the service quality, effectively enhanced customer stickiness, achieved orderly growth in sales performance with core customers during the Reporting Period, and consolidated the competitive advantage of the main channels with public hospitals. The steady development of fundamentals of the pharmaceutical distribution segment provided solid support for the Group’s high-quality and steady development and further consolidated the Group’s leading position in the industry. Medical Device Distribution: Optimization of the business structure consolidated the foundation, and deepening cultivation of innovative projects enhanced value In 2025, the deepening implementation of the centralized volume-based procurement of medical devices and the further expansion of the scope of centralized procurement promoted the reasonable return of prices in the distribution link, and the continuous compression of profit margin in traditional distribution business accelerated the transformation of distribution enterprises into supply chain service providers. The reform of medical insurance payment (Diagnosis Related Group (DRG)/Diagnosis-Intervention Packet (DIP)) has achieved comprehensive coverage, and the demand for hospital cost control has spawned the demand for refined management of consumables, and intelligent supply chain solutions have ushered in broad development opportunities. The normalization of compliance regulation in the medical field was promoted, covering the whole process and whole scenario of pharmaceutical purchase and sale, focusing on standardizing the procurement of equipment, the distribution of consumables and other areas, and accelerating the purification of industry ecology. Under the synergistic effect of various policies, the increasing concentration of the medical device distribution industry has become more and more obvious. Sticking to the compliance bottom line, focusing on the main responsibilities and business and improving the service capability of supply chain have become the core competitiveness of enterprises for long-term development.
- 29 -
In terms of medical device distribution segment, the Group proactively responded to the needs of industry policies and regulatory changes, and expanded high value-added services through the operation strategies for optimizing business structure, strengthening compliance management and control and focusing on high-quality businesses, thus consolidating the development foundation of the segment. As of the end of the Reporting Period, the medical device distribution segment recorded an annual operating income of RMB115,537.72 million, represent a year-on-year decrease of 2.02%. The Group proactively adjusted its business structure for the medical device distribution segment, strengthened appropriate sales control of inefficient businesses with long payment terms and low profit contribution, reduced operation risks, increased the revenue proportions of businesses with high value-added and high customer stickiness, and continuously optimized revenue sources. Meanwhile, the Group actively promoted the reform of segment businesses, adhered to compliance operation, proactively purified the industry environment, and adapted to the general trend of high-quality development of the pharmaceutical and healthcare industry. As of the end of the Reporting Period, the sales revenue of the Group’s SPD and centralized distribution projects achieved double-digit growth on a year-on-year basis, and the performance contribution of new SPD, medical consortium and medical communities projects continued to be released. From the perspective of the structure of products, during the Reporting Period, medical consumables products achieved sustained and steady growth by relying on the expansion of primary health and the support of the essential clinical demand; the sales of IVD products and medical devices were affected by the policy for “replacing the old for new ones” and the slow centralized procurement speed brought by the price reduction of centralized procurement and the normalization of compliance supervision, resulting in a decline in business income. The overall operating profit margin of the medical device distribution segment was 2.23%, representing a slight decrease of 0.02 percentage point compared with the same period of last year, mainly due to the decrease of gross profit and gross profit margin of the segment. During the Reporting Period, the Group actively expanded intelligent supply chain innovation projects based on customer needs and guided by compliance and value creation, and continuously improved the revenue from services and market coverage. As of the end of the Reporting Period, the Group’s intelligent supply chain projects of medical devices covered the medical institutions in 30 provinces in China, and the Group added 72 SPD projects, 68 single hospital centralized distribution projects and 4 medical consortium/medical communities centralized distribution projects throughout the year, and the service network and service depth continued to expand. Meanwhile, the Group continued to deepen the construction of the whole process and standardization system of medical device SPD projects, accelerated the penetration of SPD services in the target market, made efforts to build a nationwide and interconnected intelligent supply chain service platform for medical devices, and consolidated the Group’s leading position in the field of the intelligent supply chain of medical devices.
- 30 -
Retail Pharmacy: Synergy between wholesale and retail released growth momentum, and lean operation enhanced the quality and efficiency of development In 2025, with the active promotion by the National Healthcare Security Administration, the centralized volume-based procurement of drugs “entering primary medical institutions, private hospitals and retail pharmacies” (the “Three Entrances”) has been fully launched in all provinces across the country. Retail pharmacies have become an important channel to ensure the accessibility of centralized procurement drugs. With the convergence of the prices of centralized procurement drugs in pharmacies and medical institutions, patients gradually returned from hospitals to retail pharmacies to buy drugs, paving the way for retail pharmacies to further undertake prescription flow. The implementation of the “Three Entrances” policy has objectively put forward higher requirements for the management capability of pharmaceutical retail enterprises. Enterprises are required to continuously enhance the building of the professional capacity of pharmacy service while strengthening the capabilities of cost control and supply chain integration, and foster the upstream and downstream collaboration of the industrial chain and the innovation capability of health services around end customers, so as to expand income sources and improve the overall profitability on the basis of reducing costs and increasing efficiency. Leading retail enterprises are expected to seize the development opportunities in the industry reform with their resource integration capabilities, collaborative innovation capabilities and lean operation level. In 2025, the Group actively responded to the requirements of industry policies, gave full play to its strong advantages of lean management and compliant operation, and thoroughly advanced the “wholesaleretail integration” and the “dual-brand” collaborative strategy by taking the strengthening of service capabilities and integrated operation as the starting point to promote the high-quality development of the retail pharmacy business. During the Reporting Period, the Group’s retail pharmacy segment achieved outstanding results, and its annual revenue of the segment recorded RMB38,382.77 million, representing a year-on-year increase of 6.67%. Among which, due to the impact of factors such as the overall market environment, the intensified industry competition and optimization of the store structure, the sales revenue of the Guoda Drugstore system recorded RMB20,981 million, representing a yearon-year decrease of 6.16%. However, benefiting from the positive response to market changes and the rapid implementation of a series of measures such as enhancing the governance efficiency, reducing expenses and adjusting the structure of category, Guoda Drugstore achieved remarkable improvement in its operating efficiency. As of the end of the Reporting Period, the net profit of Guoda Drugstore achieved positive growth after excluding the impact of the impairment of goodwill and intangible assets, representing a year-on-year growth of 139%. The sales revenue of the specialty pharmacy system based on operational statistics maintained a high-speed growth of more than 15% by relying on the advantages of the undertaking of out-of-hospital prescriptions and the synergy of wholesale and retail, which had become a strong growth driving force for the retail segment, and the overall business structure continued to be optimized in the direction of high value-added professional services. The overall operating profit margin of the retail pharmacy segment was 1.56%, representing a year-on-year increase of 0.66 percentage point, mainly attributable to the effectiveness of governance measures for the retail pharmacy segment, significant decrease in the overall expenses and the enhancement of profitability.
- 31 -
During the Reporting Period, Guoda Drugstore proactively adapted to the changes in the competitive landscape of the industry, and comprehensively promoted lean operation and upgraded the internal governance by focusing on the improvement of operating quality, the optimization of store structure and the improvement of efficiency. The Company firmly implemented strategic store closure and differentiated layout, focused on improving the profit and the quality, and closed the inefficient stores with poor operation efficiency and long-term losses in an orderly manner. Meanwhile, the Company steadily expanded the network layout in core cities and high-quality communities, and further optimized the overall store structure. As of the end of the Reporting Period, the number of stores of Guoda Drugstore was 8,221, representing a net decrease of 1,348 stores compared with the same period of last year. Secondly, Guoda Drugstore solidly advanced the internal unified procurement strategy and integrated management. As of the end of the Reporting Period, the internal unified procurement rate reached nearly 70%, effectively reducing procurement costs and significantly improving the operational efficiency, the per capita efficiency and the profitability. The specialty pharmacy system focused on strengthening its service capability, accelerating the construction of a patient-centered health service platform, vigorously connecting with prescription hospitals, and further enhancing the sales contribution brought by undertaking prescription traffic. Meanwhile, the specialty pharmacy system strengthened in-depth cooperation with upstream pharmaceutical companies by relying on the core advantages of wholesale and retail integration. During the Reporting Period, the Group reached the goal of unified national cooperation and promotion with 13 large pharmaceutical enterprises in terms of the retail business, enhanced the service stickiness of upstream suppliers with professional services, and at the same time empowered the development of the distribution segment, and continued to explore the profit growth point of the specialty pharmacy. As of the end of the Reporting Period, the number of the stores of specialty pharmacy was 1,461, representing a net decrease of 183 stores compared with the same period of last year. The specialty pharmacy has always been committed to providing C-side customers with compliant, convenient and full-process medication services and health management, exploring the establishment of innovative and professional service models with upstream suppliers and downstream hospital-side customers, creating standard processes and industry benchmarks for various business scenario services, steadily enhancing its market competitiveness, continuously consolidating the Group’s leading position in the field of specialty pharmacy, and expanding opportunities for the Group’s long-term high-quality growth.
- 32 -
Operation Management and Control and Transformation Upgrading: Integrated management and control and digital transformation achieved remarkable results, and lean operation drove value creation In 2025, the Group comprehensively promoted the “integrated” management and control strategy and the “centralized” management mode, formulated a number of integrated action plans, covering the business integration and the management integration, refined the three-year implementation plan, continuously strengthened the in-depth and penetrating management and control and the flat management capability, and improved the operational efficiency throughout the chain, laying a solid foundation for the Group’s high-quality development. As of the end of the Reporting Period, the Group steadily promoted the procurement integration, and the unified procurement rate of drugs in the province reached approximately 55%, representing an increase of nearly 16 percentage points compared with the same period of last year, and the Group effectively helped to control costs through deep integration of regional resources. Meanwhile, the promotion of procurement integration enhanced the inventory transparency, optimized the inventory structure and improved inventory turnover days, and the internal synergy efficiency was significantly enhanced. In terms of logistics integration, the Group promoted the re-planning and integration of national and regional storage resources and optimized the allocation of resources to improve the logistics efficiency. Logistics costs reduced year on year, and the intensification and operational efficiency of storage resources significantly improved. In terms of management integration, the Group pushed forward centralized management, accelerated the transformation of grassroots enterprises to business front end, incorporated the human resources, finance and operational functions of low-level enterprises into higher-level companies for centralized management, consolidated the vertical management and control of the organization, helped the headquarters’ management output, and optimized the overall operational efficiency. Through the promotion of centralized management, the performance of inefficient enterprises of the Group was improved and the integration construction achieved remarkable results during the Reporting Period. The Group profoundly recognized that deeply promoting the digitalization strategy and tapping the strategic value of data assets are the key engines to continuously drive the transformation and development. The Group has the basic advantages of covering the core data of the industrial chain including drugs and medical devices products, terminal procurement and consumption, warehousing and logistics, which is a solid base for developing data products in the future and exploring the multipath value potential. Deeply tapping into the strategic value of data assets and exploring the deep integration of data assets and traditional distribution business will open up a wealth of possibilities for the Group to innovate business models, build core competitiveness and seize the development opportunities of digital economy. Solidly promoting digital transformation is a prerequisite for releasing the value and potential of data assets. During the Reporting Period, the Group deeply promoted its digital transformation, accelerated the implementation of digital transformation, fully empowered its business development and completed the implementation of a large number of digital projects. As of the end of the Reporting Period, the Group had completed the governance of master data of all business, formed an integrated data management system, harmonized full-scale operational data across core business segments, and realized digital penetration management of key business scenarios. In the field of logistics, digital and visual operation management had covered six major logistics hubs and two provincial logistics centers, initially realizing the transformation from “decision-making by
- 33 -
experience” to “decision-making by data”. In addition, the Group had fully implemented the collection and uploading of traceability code data of all legal entities involved in medical insurance traceability codes in the distribution segment, completed the deployment of drug traceability codes by the National Healthcare Security Administration with high quality, actively responded to regulatory requirements and ensured the efficient use of medical insurance funds. The digital transformation strategy fully empowered lean operation and scientific decision-making, laying a solid foundation for the Group to explore intelligent application innovation in various business fields. In terms of operational management and control, the Group focused on improving core financial indicators and operational quality and efficiency through a series of refined control measures. Benefited from measures such as cost reduction, further promotion of integrated management and control and optimization of financing strategy, the Group’s expenses during the Reporting Period continued to decline. Among which, sales and management expense ratio decreased by 0.19 percentage point year on year to 4.18%; the finance expense ratio decreased by 0.05 percentage point year on year to 0.35%; and the overall expense ratio decreased by 0.25 percentage point year on year to 4.52%. Amid pressure on the revenue side, the effective control of the overall expense ratio provided a strong support to the Group for smoothing out the downward pressure on the gross profit margin and maintaining profitability resilience. Secondly, during the Reporting Period, the Group strengthened the management and control of the risk of accounts receivable, and implemented special governance actions for the collection of accounts receivable, focused on the decline of accounts receivable with a maturity of more than one year and improved the collection structure. As of the end of the Reporting Period, the increase of accounts receivable of the Group has been effectively controlled. The increase in accounts receivable with a maturity of more than one year significantly declined compared with the same period of last year, and the special governance on accounts receivable achieved remarkable results. As of the end of 2025, the net inflow of the Group’s operating cash flow increased by RMB2,592.2 million year on year, representing an increase of 22.45%, which firmly promoted the transformation of the Group’s development model from scale-oriented to quality and cash flow-oriented. As of the end of the Reporting Period, the overall asset-liability ratio of the Group was 65.63%, representing a year-on-year decrease of 2.12 percentage points, and the capital structure continued to be optimized in the steady development.
- 34 -
Future Prospects The year 2026 is a year for laying the groundwork for the “15th Five-Year” Plan. Sinopharm will unswervingly promote its high-quality development with the fundamental purpose of serving the national strategy and ensuring people’s livelihood. In the new year, the Group will continue to scientifically analyze industry policies and competition landscape, base itself on the new development stage, focus on the main responsibilities and business, deepen business transformation and innovation-driven, continuously strengthen lean operation and compliance risk management and control, ensure stable and orderly operation development, and constantly consolidate its leading position of the industry. Pharmaceutical and Medical Device Distribution: Stabilize the advantages of main business through differentiation strategies, and leverage policies to expand the market share In terms of the pharmaceutical and medical device distribution segment, the Group will consolidate its dominant position in core cities through differentiated regional market strategies, accelerate the expansion of market share in potential cities and systematically increase its national market share. Secondly, the Group will focus on core hospital customers, tap the core needs of customers with professional services and strive to increase the share and growth rate of key hospitals. Meanwhile, the Group will continue to seize the development opportunities of the primary medical market, expand the network coverage in an orderly manner, and improve the accessibility of drugs. In the face of the normalization and institutionalization of the national negotiated policy and the volume-based procurement policy, the Group will actively strive for the distribution right of centralized procurement varieties and promote the intensification of procurement and the scale of distribution, and the Group will give priority to the introduction of high-value national negotiated varieties, focus on new varieties and policies of innovative drug companies, increase the introduction of innovative drugs, and deepen the cooperation with upstream manufacturers. Retail Pharmacy: Synergistic development under the “dual-brand” strategy, and profit growth driven by professional services In terms of the retail pharmacy segment, the Group will adhere to the synergistic development strategy of the Guoda Drugstore system and the specialty pharmacy system, focus on the essence of serving C-side customers, continuously strengthen its professional pharmacy service capability, and build the core competitiveness of retail drug stores. The Guoda Drugstore system will strengthen in-depth management and continuously improve the operation quality and efficiency of a single store, further optimize the structure of categories and increase the proportion of unified procurement and own brands, strengthen compliance risk control and management, empower traditional business with digital intelligence and promote refined operations and precision marketing. The specialty pharmacy system will give full play to the advantage of wholesale-retail integration, focus on laying out the hospital-side stores of core medical institutions around the dividend of the policy for the outflow of prescriptions, and continuously improve the market coverage. The Group will adhere to strengthen the innovation and standardization construction of commercial models of the business scenarios of the specialty pharmacy such as prescription circulation center and chronic disease management center, provide customers with personalized and comprehensive one-stop medication management and health services, and broaden the service value increment of business scenarios of the specialty pharmacy.
- 35 -
Operation Management and Control and Transformation Upgrading: Further advancing the integration and digitalization, lean management and service transformation drive quality and efficiency improvement The Group will firmly promote the implementation of the integrated strategy and the empowerment of digital transformation, inject strong momentum into long-term development, continue to promote the integration of various professional fields, and strengthen the capability of vertical penetration control. Guided by the improvement of operation, the Group will steadily implement centralized management in the middle and back offices of grassroots enterprises, further increase the proportion of unified procurement of drugs in the province and effectively reduce the comprehensive procurement cost, and promote the building of the integration of logistics network system in an orderly manner. In the field of digital transformation, the Group will formulate and implement special plans, clarify the top-level design and implementation paths, and focus on advancing the implementation of core group unified systems such as financial integration, procurement integration and logistics integration to help organizational transformation, business empowerment and control. In terms of deepening the application of data value, the Group will actively explore the implementation of the innovation of artificial intelligence in related high-value business scenarios and the strategic value of data assets, and drive the transformation of the operational efficiency with technological innovation. In terms of lean management, the Group will continue to focus on the core goal of reducing costs and increasing efficiency, and strive to comprehensively enhance its core competitiveness. On the one hand, the Group will continue to deepen the governance of accounts receivable, focus on promoting credit management of customers, and make every effort to improve the quality of asset and the turnover efficiency of funds. On the other hand, the Group will deeply promote the refinement of cost control, reduce the overall operating cost, continuously improve the per capita efficiency by taking “per capita profit” as the core indicator, deeply tap the benefits from the internal efficiency, and give full play to the scale effect of the enterprise. In addition, the Group will persist in improving the construction of the compliance management system, and support its steady development at the critical stage of industry transformation with the solid and reliable compliance management system. In terms of service transformation, the Group will actively promote the extension of professional and personalized value-added services to upstream and downstream supply chains, and promote the collaborative empowerment of main business segments and innovative services, so as to realize the reconstruction and promotion of the industrial chain value. In the future, the Group will focus on strengthening the construction of marketing service organization, enhancing the professional capability of the CSO team and strengthening the guarantee of the compliance system; the Group will vigorously expand the layout of SPD projects, accelerate the coverage of projects of core hospital terminals, and provide customized innovative service solutions based on customer needs; the Group will actively explore the new business of third-party logistics, cultivate new profit growth points, and strengthen the internal resource synergy of the Group and the coordination of national projects.
- 36 -
Standing at a new starting point, the Group will stick to the mission of central enterprises, take the strategy of serving a healthy China as its own responsibility, lay a solid foundation by focusing on the main business, integrate innovation to drive transformation, and improve the efficiency through lean management. Facing the opportunities and challenges in the future, the Group is confident that it will continue to promote innovation transformation and efficiency change with firm strategic determination and efficient execution capability, and strive to achieve its high-quality development in the new stage of industry transformation and development.
- 37 -
Financial Summary The financial summary set out below is extracted from the audited financial statements of the Group for the Reporting Period which were prepared in accordance with the HKFRS Accounting Standards: During the Reporting Period, the Group recorded a revenue of RMB575,167.88 million, representing a decrease of RMB9,340.05 million or 1.60% as compared with the corresponding period of last year. During the Reporting Period, the Group recorded a profit of RMB10,834.43 million, representing an increase of RMB410.84 million or 3.94% as compared with the corresponding period of last year. Profit attributable to owners of the parent amounted to RMB7,155.09 million, representing an increase of RMB105.41 million or 1.50% as compared with the corresponding period of last year. During the Reporting Period, basic earnings per share of the Company amounted to RMB2.29, representing an increase of 1.33% as compared with the corresponding period of last year. Revenue During the Reporting Period, the Group recorded a revenue of RMB575,167.88 million, representing a decrease of 1.60% as compared with RMB584,507.93 million for the twelve months ended 31 December 2024, which was primarily due to the decrease in revenue from the Group’s pharmaceutical distribution, medical device distribution business and other business segments. •
Pharmaceutical distribution segment: during the Reporting Period, the revenue from pharmaceutical distribution of the Group was RMB435,391.60 million, which accounted for 72.79% of the total revenue of the Group and represented a decrease of 2.02% as compared with RMB444,364.61 million for the twelve months ended 31 December 2024. The decrease was mainly due to the implementation of policies such as volume-based procurement and price reductions for nationally negotiated drugs, as well as intensified market competition, resulting in a decline in the revenue volume of the pharmaceutical distribution business.
•
Medical device distribution segment: during the Reporting Period, the revenue from medical device distribution of the Group was RMB115,537.72 million, which accounted for 19.32% of the total revenue of the Group and represented a decrease of 2.02% as compared with RMB117,915.14 million for the twelve months ended 31 December 2024. The decline was primarily attributable to the implementation of volume-based procurement policies, leading to a decrease in sales revenue from medical device categories with higher gross margins.
•
Retail pharmacy segment: during the Reporting Period, the revenue from retail pharmacy of the Group was RMB38,382.77 million, which accounted for 6.42% of the total revenue of the Group and represented an increase of 6.67% as compared with RMB35,981.26 million for the twelve months ended 31 December 2024. The increase was primarily due to the increase of sales revenue from specialty pharmacy of the Group.
- 38 -
•
Other business segments: during the Reporting Period, the revenue from other business of the Group was RMB8,852.93 million, representing a decrease of 2.78% as compared with RMB9,106.49 million for the twelve months ended 31 December 2024. The decrease was primarily due to the decrease in industrial product revenue.
Cost of Sales During the Reporting Period, the cost of sales of the Group was RMB533,495.86 million, representing a decrease of 1.25% as compared with RMB540,252.54 million for the twelve months ended 31 December 2024. The decrease was primarily due to the decrease in the revenue of the Group. Gross Profit As a result of the above-mentioned factors, the gross profit of the Group during the Reporting Period was RMB41,672.01 million, representing a decrease of 5.84% as compared with RMB44,255.39 million for the twelve months ended 31 December 2024. The gross profit margin of the Group for the twelve months ended 31 December 2025 and 2024 were 7.25% and 7.57%, respectively. Other Income During the Reporting Period, other income of the Group was RMB428.51 million, representing a decrease of 8.56% as compared with RMB468.62 million for the twelve months ended 31 December 2024. The decrease was primarily due to the decrease in subsidies obtained by the Group from the central and local governments. Selling and Distribution Expenses During the Reporting Period, the selling and distribution expenses of the Group were RMB16,181.31 million, representing a decrease of 5.70% as compared with RMB17,158.64 million for the twelve months ended 31 December 2024. The decrease in selling and distribution expenses was primarily attributable to the reduction in market expenses and compensation of the Group. Administrative Expenses During the Reporting Period, the administrative expenses of the Group were RMB7,837.63 million, representing a decrease of 6.85% as compared with RMB8,413.54 million for the twelve months ended 31 December 2024. The decrease in administrative expenses was primarily attributable to the decrease in employee compensation of the Group.
- 39 -
Operating Profit As a result of the above-mentioned factors, the operating profit of the Group during the Reporting Period was RMB16,038.22 million, representing a decrease of 0.93% from RMB16,188.40 million for the twelve months ended 31 December 2024. Other Gains – Net During the Reporting Period, the other gains – net of the Group increased from RMB46.92 million for the twelve months ended 31 December 2024 to RMB99.18 million for the Reporting Period, mainly due to the decrease in losses from financial assets held by the Group at fair value through profit or loss. Other Expenses During the Reporting Period, the other expenses of the Group amounted to RMB575.77 million, representing a decrease of RMB529.81 million as compared with RMB1,105.58 million for the twelve months ended 31 December 2024, mainly attributable to the reduction in provision for impairment loss of intangible assets recognized during the year. Finance Costs – Net During the Reporting Period, the finance costs – net of the Group was RMB1,994.91 million, representing a decrease of 14.32% as compared with RMB2,328.24 million for the twelve months ended 31 December 2024. The decrease was primarily due to the decrease of the borrowing interest rates and adjustments to the financing structure during the year. Share of Profits of Associates During the Reporting Period, the Group’s share of profits of associates was RMB1,230.08 million, representing an increase of 2.81% as compared with RMB1,196.48 million for the twelve months ended 31 December 2024. Share of Profits and Losses of Joint Ventures During the Reporting Period, the Group’s share of profits of joint ventures was RMB2.83 million, representing a decrease of 3.12% as compared with RMB2.92 million for the twelve months ended 31 December 2024.
- 40 -
Income Tax Expenses During the Reporting Period, the Group’s income tax expenses were RMB3,965.19 million, representing an increase of RMB387.88 million as compared with RMB3,577.31 million for the twelve months ended 31 December 2024. The increase was primarily due to the increase in profit before tax of the Group, which led to a corresponding increase in income tax expenses. The Group’s actual income tax rate increased to 26.79% during the Reporting Period from 25.55% for the twelve months ended 31 December 2024. Profit for the Year As a result of the above-mentioned factors, the profit of the Group for the year of 2025 was RMB10,834.43 million, representing an increase of 3.94% as compared with RMB10,423.59 million for the twelve months ended 31 December 2024. The annual profit margin of the Group for the twelve months ended 31 December 2025 and 2024 were 1.88% and 1.78%, respectively. Profit Attributable to Owners of the Parent During the Reporting Period, profit attributable to owners of the parent of the Company was RMB7,155.09 million, representing an increase of 1.50% or RMB105.41 million from RMB7,049.68 million for the twelve months ended 31 December 2024. Profit Attributable to Non-controlling Interests During the Reporting Period, profit attributable to non-controlling interests of the Company was RMB3,679.34 million, representing an increase of 9.05% or RMB305.43 million from RMB3,373.91 million for the twelve months ended 31 December 2024. Liquidity and Capital Resources Working capital During the Reporting Period, the Group had commercial banking facilities of RMB324,753.19 million, of which approximately RMB201,040.79 million were not yet utilized. As at 31 December 2025, the Group had cash and cash equivalents of RMB48,796.13 million, which primarily comprised cash and bank savings.
- 41 -
Cash flow The cash of the Group was primarily used for financing working capital, repaying credit interest and principal due, financing acquisitions and providing funds for capital expenditures, growth and expansion of the Group’s facilities and operations. The table below sets out the cash flow of the Group from operating, investing and financing activities for the year ended 31 December 2025 and 2024, respectively: 2025 RMB million
2024 RMB million
Net cash generated from operating activities Net cash used in investing activities Net cash used in financing activities Decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the year Foreign exchange gain and loss
14,138.21 (963.89) (18,686.65) (5,512.33) 54,313.36 (4.90)
11,546.01 (3,750.92) (17,285.03) (9,489.94) 63,808.54 (5.24)
Cash and cash equivalents at the end of the year
48,796.13
54,313.36
Net cash generated from operating activities The Group’s cash inflow from operations primarily derives from collections from the sale of the products and services in its pharmaceutical distribution, retail pharmacy, medical device distribution and other business segments. During the Reporting Period, the Group’s net cash generated from operating activities amounted to RMB14,138.21 million, representing an increase of RMB2,592.20 million from RMB11,546.01 million for the twelve months ended 31 December 2024. Net cash used in investing activities During the Reporting Period, the net cash used in investing activities of the Group was RMB963.89 million, representing an decrease of RMB2,787.03 million as compared with RMB3,750.92 million for the twelve months ended 31 December 2024.
- 42 -
Net cash used in financing activities During the Reporting Period, the net cash used in financing activities of the Group was RMB18,686.65 million. The net cash used in financing activities of the Group for the twelve months ended 31 December 2024 was RMB17,285.03 million, and such increase was mainly due to the repayment of interest-bearing bank borrowings and other borrowings during the period. Capital Expenditure The Group’s capital expenditures were primarily utilized for the development and expansion of distribution channels, upgrading of its logistic delivery systems and the improvement of the level of informatization. The Group’s capital expenditures amounted to RMB1,917.30 million and RMB2,460.69 million for the year ended 31 December 2025 and 2024, respectively, which was primarily due to the decrease in expenditure on the purchase of property, plant and equipment. The Group’s current plans with respect to its capital expenditures may be modified according to the progress of its operation plans (including changes in market conditions, competition and other factors). As the Group continues to develop, it may incur additional capital expenditure. The Group’s ability to obtain additional funding in future is subject to a variety of factors, including its future operational results, financial condition and cash flows, economic, political and other conditions in the mainland China and Hong Kong, and the PRC Government’s policies relating to foreign currency borrowings, etc. Capital Structure Fiscal resources and fiscal policies During the Reporting Period, the Group made certain improvement and adjustments to its capital structure, so as to relieve fiscal risks and reduce finance costs. The Group’s business faced a variety of fiscal risks: market risk (including foreign exchange risk, fair value and cash flow interest rate risk), credit risk and liquidity risk. The Group’s risk management addresses the unpredictability of financial markets and minimises potential adverse effects on the Group’s financial performance. The Group didn’t use derivative financial instruments to hedge its exposure to changes in foreign currency exchange rates and interest rates. The Group had successfully issued super short-term financing bonds in an aggregate amount of RMB3.8 billion during the Reporting Period for the purposes of broadening financing channels and reducing financing costs, so as to repay bank loans as well as to replenish working capital. The Group’s borrowings are mainly denominated in RMB. As at 31 December 2025, the cash and cash equivalents of the Group were mainly denominated in RMB, with certain amount denominated in United States Dollars (“USD”) and Hong Kong Dollars (“HKD”), Great Britain Pound (“GBP”), Swiss Franc (“CHF”) and Japanese Yen (“JPY”).
- 43 -
Indebtedness As at 31 December 2025, the Group had aggregated banking facilities of RMB324,753.19 million (31 December 2024: RMB310,604.69 million), of which RMB201,040.79 million (31 December 2024: RMB173,910.33 million) were not utilized and are available to be drawn down at any time. Such banking facilities are primarily short-term loans for working capital. Among the Group’s total borrowings as at 31 December 2025, RMB63,321.16 million (31 December 2024: RMB62,729.05 million) will be due within one year and RMB3,645.48 million (31 December 2024: RMB8,637.23 million) will be due after one year. During the Reporting Period, the Group did not experience any difficulties in renewing its bank loans with its lenders. As at 31 December 2025, bank borrowings and other financial institutions borrowings of the Group were carried at floating interest rates with a weighted average effective annual interest rate of 2.50% for the year ended 31 December 2025 (for the year ended 31 December 2024: 2.62%). Gearing ratio As at 31 December 2025, the Group’s gearing ratio was 65.63% (31 December 2024: 67.75%), which was calculated based on the total liabilities divided by total assets as at 31 December 2025. Credit Risk The Group will focus on the recovery of account receivables with a maturity of more than one year, inventory risk and liquidity control, credit exposure and other potential risks, coordinate development and safety, continuously improve the level of compliance supervision, and prevent and control business operation risks. Meanwhile, the Group will continue to review the credit risk of trade receivables and fully consider changes in business structure and customer structure, changes in the macroeconomic environment and specific industry factors. At the same time, the Group will also continue to review the Group’s customer credit risk characteristic portfolios to ensure that the division of credit risk characteristic portfolios can fully reflect the risk characteristics of different types of customers, and the Group will assess the accounting estimates such as historical observed default rates and forwardlooking adjustments in a more prudent manner to ensure that the provision matrix of the Group’s expected credit loss can fully reflect the impairment provisions for trade receivables. As at 31 December 2025, the trade and bills receivables of the Group in aggregate amounted to RMB205,622 million (31 December 2024: RMB200,255 million) and its aging analysis is set out in Note 13 to the consolidated financial statements.
- 44 -
The Group has established a sound customer credit management system and trade receivables management measures to prevent credit risks and improve the turnover efficiency of trade receivables, and major measures included but not limited to: (i) establishing a scientific and rational credit evaluation model to strictly review and approve customers’ credit limits; (ii) reviewing the actual sales, collection of trade receivables and financial information of customers on a regular basis, and implementing a dynamic management on customers’ credit limits and terms; (iii) strengthening the regular monitoring and analysis of several indicators such as the balance of trade receivables with a maturity of more than one year, balance of trade receivables overdue and turnover days of trade receivables based on different customer bases; and (iv) strengthening the reconciliation and collection of trade receivables, especially receivables with a maturity of more than one year and overdue receivables, developing practical collection measures and repayment terms, and other necessary measures. Foreign Exchange Risks The Group’s operations are mainly located in the PRC and most of its transactions are denominated and settled in RMB. However, the Group is exposed to foreign exchange risks to some extend on certain cash and cash equivalents, prepayments and other receivables, trade payables and accrued expenses and other payables denominated in foreign currencies, the majority of which are USD, HKD and EUR. During the Reporting Period, the Group has no corresponding hedging arrangements. Pledge of Assets As at 31 December 2025, part of the Group’s borrowings and notes payable were secured by trade and notes receivable with book value of RMB2,146.10 million (31 December 2024: RMB2,214.32 million), bank deposits of RMB10,138.92 million (31 December 2024: RMB10,200.79 million), and property, plant and equipment with book value of RMB0 million (31 December 2024: RMB14.90 million). Major Acquisitions and Disposals During the Reporting Period, the Group had no major acquisitions and disposals with respect to subsidiaries, associates and joint ventures. Significant Investment During the Reporting Period, the Group had no significant investments. As at the date of this announcement, the Board has not approved any plans for material investments or purchase of capital assets. Going Concern Based on the current financial forecast and financing facilities available, the Group has sufficient financial resources for ongoing operation in the foreseeable future. As such, the financial statements were prepared on a going concern basis.
- 45 -
Contingent Liabilities and Material Litigations As at 31 December 2025, the Group neither had any material contingent liability, nor had any material litigation. Human Resources As at 31 December 2025, the Group had a total of 94,910 employees (as at 31 December 2024: 108,217 employees). The Group has always adhered to the development philosophy that “talents are the Group’s core competitiveness”. With the goal of supporting strategic implementation and driving high-quality development, the Group has established a professional and integrated human resource management system. Through scientific talent selection, systematic training and development and diverse incentive and restraint mechanisms, the Group has created a high-quality talent team. For personnel employment, the Company has established strict and standardized selection standards and procedures, adhered to the principle of selecting candidates with ability and integrity, and talentpost matching, and accurately selected outstanding talents who align with the Company’s values and job requirements, injecting fresh vitality into the Company’s sustainable development. For talent development, the Company focused on the growth needs of employees at different functions and levels, and built a tiered and categorized training system to help employees improve their professional skills and overall quality, so as to achieve the resonance between personal development of employees and strategic goals of the Company. For performance management, the Company implemented top-down performance assessment with performance contributions as the core evaluation criterion. The Company closely linked performance assessment results with remuneration adjustments, promotions and career development, fully stimulating employees’ enthusiasm and initiative in their work and entrepreneurship. For remuneration strategy, based on the principle of “performance-oriented compensation, prioritizing efficiency and considering fairness”, the Company established a compensation system with position value and ability as basis and performance contribution as the cornerstone. The employee remunerations include multiple dimensions such as basic salary, performance-based remuneration, bonus and piece rate wage. The Company further adopted a combination of short-term and medium- and long-term incentives, adhered to the performance-oriented principle while giving consideration to balance, and designed a compensation structure comprising “basic remuneration, performance-based remuneration, and medium- and long-term incentives for operational management, demonstrating the principles of “diversified structure, dynamic adjustments, value creation, the incremental value distribution, sharing benefits and risks, aligning with market benchmarks and international standards”, which promoted the formation of a community of interests between operational management and the Company and facilitated the Company to achieve its long-term strategic goals. Details of employee benefit expenses of the Group during the Reporting Period are set out in the Note 9 to the consolidated financial statements.
- 46 -
DIVIDEND POLICY The Company has established a dividend policy. Under the Company Law of the People’s Republic of China and the Articles of Association, all of our shareholders have equal rights to dividends and distribution. The declaration of dividends is subject to the discretion of the Board and the approval of the shareholders, which the Company expects will take into account factors such as the following: (i)
the Company’s financial results;
(ii)
the Company’s shareholders’ interests;
(iii) general business conditions and strategies; (iv) the Company’s capital needs; (v)
contractual restrictions on the payment of dividends by the Company to its shareholders or by the Company’s subsidiaries to the Company;
(vi) taxation considerations; (vii) possible effects on the Company’s credit worthiness; (viii) statutory and regulatory restrictions; and (ix) any other factors the Board may deem relevant. The allocations to the statutory common reserve fund are currently determined to be 10% of the Company’s after-tax profit attributable to equity holders of the Company for the fiscal year determined in accordance with PRC accounting rules and regulations. When the accumulated allocations to the statutory common reserve fund reach 50% of the Company’s registered capital, the Company will no longer be required to make allowances for allocation to the statutory common reserve fund. DIVIDENDS Relevant resolution was passed at a meeting of the Board held on 20 March 2026 to propose to distribute a final dividend of RMB0.69 per share (tax inclusive) for the year ended 31 December 2025 (the “Final Dividend”), totalling approximately RMB2,153,253,000. If the proposal of profit distribution is approved by shareholders at the 2025 annual general meeting to be held on Thursday, 18 June 2026 (the “AGM”), the Final Dividend will be distributed to the shareholders whose names appear on the register of members of the Company on Tuesday, 30 June 2026 no later than 18 August 2026.
- 47 -
According to the Articles of Association of the Company, the Final Dividends will be denominated and declared in Renminbi. Final Dividend on domestic shares of the Company and for investors investing in the H shares of the Company through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect (the “Southbound Trading”) (the “Southbound Trading Shareholders”) will be paid in Renminbi, and the Final Dividend for other holders of H shares of the Company will be paid in Hong Kong dollars. The amount of the Final Dividend payable in Hong Kong dollars shall be calculated based on the average exchange rate of Renminbi to Hong Kong dollars as announced by the People’s Bank of China for the calendar week prior to 18 June 2026 (being the date of declaration of the Final Dividend). For the Southbound Trading Shareholders, the Company has entered into the Agreement on Distribution of Cash Dividends of H Shares for Southbound Trading (港股通H股股票現金紅利派發協議) with China Securities Depository and Clearing Corporation Limited, pursuant to which, the Shanghai Branch and Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, each of which as a nominee of the holders of H shares for Southbound Trading, will receive all the Final Dividend distributed by the Company and distribute the Final Dividend to the relevant Southbound Trading Shareholders through their depositary and clearing systems. Pursuant to the Enterprise Income Tax Law of the PRC and its implementing regulations (hereinafter collectively referred to as the “EIT Law”), the tax rate of the enterprise income tax applicable to the income of non-resident enterprise deriving from the PRC is 10%. For this purpose, any H shares registered under the name of non-individual enterprise, including the H shares registered under the name of HKSCC Nominees Limited, other nominees or trustees, or other organizations or entities, shall be deemed as shares held by non-resident enterprise shareholders as defined under the EIT Law. The Company will distribute the Final Dividend to non-resident enterprise shareholders subject to a deduction of 10% enterprise income tax withheld and paid by the Company on their behalf. Any resident enterprise as defined under the EIT Law which has been legally incorporated in the PRC or which has established effective administrative entities in the PRC pursuant to the laws of foreign countries (regions) and whose name appears on the register of the members of H shares of the Company should deliver a legal opinion ascertaining its status as a resident enterprise furnished by a PRC lawyer (with the official chop of the issuing law firm affixed thereon) and relevant documents to Computershare Hong Kong Investor Services Limited in due course, if they do not wish to have the 10% enterprise income tax withheld and paid on their behalf by the Company.
- 48 -
Pursuant to the Notice on the Issues on Levy of Individual Income Tax after the Abolishment of Guo Shui Fa [1993] No. 045 Document (the “Notice”) issued by the State Administration of Tax on 28 June 2011, the dividend to be distributed by the PRC non-foreign invested enterprises which have issued shares in Hong Kong to the overseas resident individual shareholders, is subject to the individual income tax with a tax rate of 10% in general. However, the tax rates for respective overseas resident individual shareholders may vary depending on the relevant tax agreements between the countries of their residence and Mainland China. Thus, 10% personal income tax will be withheld by the Company from the Final Dividend payable to the individual H-share shareholders whose names appear on the register of members of the Company on Tuesday, 30 June 2026, unless otherwise stated in the relevant taxation regulations, taxation agreements or the Notice. If individual H Share shareholders consider that the tax rate adopted by the Company for the withholding and payment of individual income tax on their behalf is not the same as the tax rate stipulated in any tax treaties between the PRC and the countries (regions) in which they are domiciled, after receiving the dividends, they may proceed with the subsequent tax related treatment in person or through proxy with competent tax authorities of the Company in accordance with requirements under the tax treaties. Pursuant to the “Notice on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shanghai and Hong Kong Stock Markets” (Cai Shui [2014] No. 81) (《關於滬港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2014]81號)) and the “Notice on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shenzhen and Hong Kong Stock Markets” (Cai Shui [2016] No. 127) (《關於深 港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2016]127號)) jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the China Securities Regulatory Commission, for dividends derived by Mainland individual investors from investing in H-share listed on the Hong Kong Stock Exchange through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect, H-share companies shall withhold individual income tax at a tax rate of 20% for the investors. For Mainland securities investment funds investing in shares listed on Hong Kong Stock Exchange through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect, the above rules also apply and individual income tax shall be levied on dividends derived therefrom. Dividends derived by Mainland enterprise investors from investing in shares listed on Hong Kong Stock Exchange through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect shall be reported and paid by the enterprise investors themselves. H-share companies will not withhold or pay enterprise income tax on their behalf in the distribution of dividends. The Company will have no liability in respect of any claims arising from any delay in, or inaccurate determination of the status of the shareholders or any disputes over the mechanism of withholding. As at the date of this announcement, the Board is not aware of any shareholders who have waived or agreed to waive any dividends.
- 49 -
CLOSURE OF REGISTER OF MEMBERS In order to ascertain Shareholders’ entitlement to attend and vote at the AGM, the register of members of the Company will be closed from Monday, 15 June 2026 to Thursday, 18 June 2026 (both days inclusive), during which period no transfer of Shares will be registered. In order to qualify to attend the AGM and to vote at the meeting, all instruments of transfer of the holders of H-shares of the Company must be lodged at the H-shares registrar of the Company at Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Friday, 12 June 2026. Shareholders whose names appear on the register of members of the Company on Monday, 15 June 2026 shall be entitled to attend the AGM. In order to ascertain Shareholders’ entitlement to receive the proposed Final Dividend, the register of members of the Company will be closed from Thursday, 25 June 2026 to Tuesday, 30 June 2026 (both days inclusive), during which period no transfer of Shares will be registered. In order to qualify to receive the Final Dividend, all instruments of transfer of the holders of H-shares of the Company must be lodged at the H-shares registrar of the Company at Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Wednesday, 24 June 2026. Shareholders whose names appear on the register of members of the Company on Tuesday, 30 June 2026 shall be entitled to receive the Final Dividend. PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES During the Reporting Period, none of the Company and its subsidiaries had purchased, sold or redeemed any of the listed securities of the Company (including sales of treasury shares (the “Treasury Shares”) within the meaning under the Rules Governing the Listing of Securities on Hong Kong Stock Exchange (the “Listing Rules”)). As at 31 December 2025, the Company did not hold any Treasury Shares. AUDIT COMMITTEE As at the date of this announcement, the audit committee of the Company consists of three directors: including three independent non-executive directors being Mr. Wu Tak Lung, Mr. Li Peiyu and Mr. Shi Shenghao. Mr. Wu Tak Lung currently serves as the chairman of the audit committee. The primary responsibilities of the Company’s audit committee are to inspect, review and supervise the Company’s financial information, reporting process for financial information and risk management and internal control system. The audit committee has reviewed the audited annual results of the Group for the year ended 31 December 2025.
- 50 -
SCOPE OF WORK OF CONFUCIUS INTERNATIONAL CPA LIMITED The financial figures in respect of the preliminary results announcement of the Group for the year ended 31 December 2025 have been agreed by the Group’s auditor, Confucius International CPA Limited, to the amounts set out in the Group’s audited consolidated financial statements for the year ended 31 December 2025. The work performed by Confucius International CPA Limited in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the HKICPA and consequently no assurance has been expressed by Confucius International CPA Limited on the preliminary results announcement. COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE (THE “CORPORATE GOVERNANCE CODE”) SET OUT IN APPENDIX C1 TO THE LISTING RULES The Company has adopted all code provisions of the Corporate Governance Code as the code of corporate governance of the Company. During the Reporting Period, the Company had complied with the code provisions as set out in the Corporate Governance Code.
- 51 -
COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS (THE “MODEL CODE”) SET OUT IN APPENDIX C3 TO THE LISTING RULES The Board has adopted the Model Code as the code of practice for directors and supervisors in respect of their trading in the listed securities of the Company. After making specific enquires with the directors and supervisors, all of them confirmed that they had complied with the requirements for securities trading of directors and supervisors set out in the Model Code during the Reporting Period. DISCLOSURE OF INFORMATION This results announcement will be published on the websites of the Company (http://www. sinopharmgroup. com.cn) and the Hong Kong Stock Exchange (http://www.hkexnews.hk). The Company’s annual report for 2025 which contains all the information required under the Listing Rules will be despatched to the shareholders according to the manner in which the shareholders of the Company have elected to receive corporate communications and published on the websites of the Company and the Hong Kong Stock Exchange in due course. By order of the Board of Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 20 March 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
- 52 -
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement dated 19 March 2026 (the “Announcement”) issued by Sinopharm Group Co. Ltd. (the “Company”) in relation to the annual report of China National Medical Device Co., Ltd. (中國醫療器械有限公司) (“CNMDC”), a subsidiary of the Company, for the year ended 31 December 2025 issued by CNMDC on the websites of China Money and Shanghai Clearing House. The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited financial data of CNMDC for the year ended 31 December 2025 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL FINANCIAL DATA OF THE CONSOLIDATED FINANCIAL STATEMENTS Unit: Yuan Currency: RMB The year of 2025
The year of 2024
Changes of this year compared with last year
Revenue
74,892,761,889.78
76,698,316,757.24
-2.35%
Operating profit
1,248,513,736.69
1,219,453,089.52
2.38%
Total comprehensive income attributable to owners of the parent company
506,755,640.47
403,336,362.93
25.64%
Net cash flow arising from operating activities
738,641,094.58
-1,356,284,840.11
-154.46%
As at 31 December 2025
As at 31 Changes of 2025 year-end over 2024 year-end December 2024
Total assets
57,302,220,888.25
61,661,013,678.38
-7.07%
Total equity attributable to owners of the parent company
8,300,052,155.36
7,884,395,529.18
5.27%
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 19 March 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
2
This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong). Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “Company”) dated 19 March 2026 (the “Announcement”) in relation to the annual report for the year ended 31 December 2025 of China National Medicines Corporation Ltd. (“SINOPHARM (CNCM LTD)”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511). The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the year ended 31 December 2025 as set out in the Announcement.
- The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”. 1
PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) Unit: Yuan Currency: RMB
Revenue
52,468,280,576.72
Changes of this year compared with last year (%) 50,597,449,788.57 3.70
Total Profit
2,600,142,573.34
2,653,612,391.50
-2.01
2,930,890,244.95
Net profit attributable to shareholders of the listed company
1,996,593,114.46
2,000,126,943.49
-0.18
2,145,998,746.54
Net profit attributable to shareholders of the listed company after deducting nonrecurring gains and losses
1,970,533,716.86
1,996,141,089.85
-1.28
2,092,945,826.67
Net cash flow arising from operating activities
2,005,517,512.06
1,659,119,523.82
20.88
2,726,657,097.53
Basic earnings per share (Yuan/Share)
2.6462
2.6509
-0.18
2.8443
Diluted earnings per share (Yuan/Share)
2.6462
2.6509
-0.18
2.8443
Basic earnings per share after deducting non-recurring gains and losses (Yuan/Share)
2.6117
2.6456
-1.28
2.7739
Weighted average return on net assets (%)
11.26
12.24
Decreased by 0.98 percentage point
13.68
Weighted average return on net assets after deducting nonrecurring gains and losses (%)
11.11
12.21
Decreased by 1.1 percentage points
13.34
Year of 2025
At the end of 2025
Year of 2024
At the end of 2024
Changes of 2025 year-end over 2024 year-end (%)
Year of 2023
49,696,045,528.87
At the end of 2023
Net assets attributable to shareholders of the listed company
18,544,719,561.48
17,128,090,785.52
8.27
15,775,887,678.80
Total assets
36,685,023,982.59
34,928,279,243.62
5.03
32,453,092,592.42
2
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 19 March 2026 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
3
SINOPHARM GROUP CO. LTD.* (A joint stock limited company incorporated in the People’s Republic of China with limited liability and carrying on business in Hong Kong as ) (Stock Code: 01099)
FORM OF PROXY FOR EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, 19 DECEMBER 2025 Number of shares to which this form of proxy relates (Note 1) I/We (Note 2) of (address) being the holder(s) of domestic shares/H shares (Note 3) of RMB1.00 each in the share capital of Sinopharm Group Co. Ltd. (the “Company”), hereby appoint the Chairman of the (Note 4) meeting or of (address) , as my/our proxy(ies) to attend the extraordinary general meeting of the Company to be held at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the People’s Republic of China (the “PRC”) at 9:30 a.m. on Friday, 19 December 2025 (the “EGM”) or any adjournment thereof and to vote at such meeting or at any adjournment thereof in respect of the resolutions set out in the notice of the EGM as hereunder indicated on behalf of me/us, or if no such indication is given, as my/our proxy(ies) thinks fit. FOR (Note 5)
ORDINARY RESOLUTIONS 1.
To consider and approve (if thought fit) the appointment of Mr. Jin Bin as a non-executive Director of the sixth session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
To consider and approve (if thought fit) the appointment of Mr. Yang Binghua as an executive Director of the sixth session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
To consider and approve (if thought fit) the appointment of Mr. Ma Yue as a non-executive Director of the sixth session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.
To consider and approve (if thought fit) the appointment of Ms. Li Ying as a non-executive Director of the sixth session of the Board, and to authorize the Board to determine her remuneration and to authorize the Chairman or any executive Director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with her.
Dated this *
day of
2025
AGAINST (Note 5)
Signature (Note 6):
The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
Notes: 1.
Please insert the number of shares of the Company registered in your name(s) to which this proxy relates. If a number is inserted, this form of proxy will be deemed to relate only to those shares. If no number is inserted, the form of proxy will be deemed to relate to all shares registered in your name(s) (whether alone or jointly with others).
Please insert the full name(s) (in Chinese or English) and address(es) as registered in the register of members of the Company in Block Letters.
Please insert the number of shares of the Company registered in your name(s) and delete as appropriate.
If any proxy other than the Chairman of the meeting of the Company is preferred, please strike out the words “the Chairman of the meeting or” and insert the name and address of the proxy desired in the space provided. A shareholder may appoint one or more proxies to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company. A proxy of a shareholder who has appointed more than one proxy may only vote on a poll. Any alteration made to this form of proxy must be initialed by the person(s) who sign(s) it.
Important: If you wish to vote for any resolution, please put a tick in the box marked “FOR” or insert the number of shares held by you. If you wish to vote against any resolution, please put a tick in the box marked “AGAINST” or insert the number of shares held by you. If you do not indicate how you wish your proxy to vote, your proxy will be entitled to exercise his discretion. Your proxy will also be entitled to vote at his discretion on any resolution properly put to the EGM other than those referred to in the notice of the EGM.
This form of proxy must be signed by you or your attorney duly authorised in writing or, in the case of a legal person, must be either executed under its seal or under the hand of its director or other attorney duly authorised to sign the same. In case of joint holders, this form of proxy must be signed by the shareholder whose name stands first in the register of members of the Company.
To be valid, for holders of H shares, this form of proxy and, if such proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority, a notarially certified copy of that power of attorney or other authority must be delivered to the H share registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for holding the EGM (or any adjournment thereof). For holders of domestic shares, this form of proxy and, if such proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority, a notarially certified copy of that power of attorney or other authority must be delivered to the office of the Company in the PRC at Room 1413, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, 200023, the PRC not less than 24 hours before the time appointed for holding the EGM (or any adjournment thereof).
In the case of joint holders of shares of the Company, only holder whose name stands first in the register of members of the Company shall alone be entitled to vote at the EGM either in person or by proxy in respect of such shares.
The EGM is expected to take less than half a day. Shareholders and their proxies who attend the meeting shall be responsible for their own travel and accommodation expenses. Shareholders shall produce their identity documents when attending the EGM.
References are made to (i) the notice of the EGM of Sinopharm Group Co. Ltd. (the “Company”) dated 4 December 2025 (the “Notice”); and (ii) the circular of the Company dated 4 December 2025 (the “Circular”). Terms used in this announcement shall have the same meanings as defined in the Circular unless the context otherwise requires. POLL RESULTS OF THE EGM The Board is pleased to announce that the EGM was held at 9:30 a.m. on Friday, 19 December 2025 at Meeting Room 1401, Sinopharm Group Building, No. 385, East Longhua Road, Huangpu District, Shanghai, the PRC. All resolutions proposed at the EGM were duly passed by way of poll. Mr. Lian Wanyong, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao, Mr. Chen Weiru, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli, being the Directors of the Company, attended the EGM.
The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.
-1 -
The poll results in respect of the resolutions proposed at the EGM are as follows:
ORDINARY RESOLUTIONS
Number of Valid Votes (%) For
- To consider and approve (if thought fit) the appointment of Mr. Jin Bin as a non-executive Director of the sixth session of the Board, and to authorize the Board to determine his remuneration and to authorize the Chairman or 2,537,365,557 any executive Director of the Company to enter into the service (95.5622%) contract or such other documents or supplemental agreements or deeds with him.
Against
117,833,143 (4.4378%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 2. To consider and approve (if thought fit) the appointment of Mr. Yang Binghua as an executive Director of the sixth session of the Board, and to authorize the Board to determine his remuneration and to authorize the 2,609,914,160 Chairman or any executive Director of the Company to enter into the (98.2618%) service contract or such other documents or supplemental agreements or deeds with him.
46,166,740 (1.7382%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 3. To consider and approve (if thought fit) the appointment of Mr. Ma Yue as a non-executive Director of the sixth session of the Board, and to authorize the Board to determine his remuneration and to authorize the 2,602,158,087 Chairman or any executive Director of the Company to enter into the (97.9698%) service contract or such other documents or supplemental agreements or deeds with him.
53,922,813 (2.0302%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. 4. To consider and approve (if thought fit) the appointment of Ms. Li Ying as a non-executive Director of the sixth session of the Board, and to authorize the Board to determine her remuneration and to authorize the Chairman or 2,608,859,388 any executive Director of the Company to enter into the service (98.2221%) contract or such other documents or supplemental agreements or deeds with her.
47,221,512 (1.7779%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution. As at the date of the EGM, the total number of issued Shares of the Company and the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the EGM was 3,120,656,191 Shares. There were no Shares entitling the Shareholders of the Company to attend and -2 -
abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules, and no holders of Shares that are required under the Hong Kong Listing Rules to abstain from voting. There were no parties who had stated their intention in the Circular to vote against the resolutions proposed at the EGM or to abstain from voting. Shareholders and authorised proxies holding an aggregate of 2,656,080,900Shares, representing approximately 85.11% of the total number of issued Shares of the Company, were present at the EGM. The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the Articles of Association. The EGM was chaired by Director Mr. Lian Wanyong. In compliance with the requirements of the Hong Kong Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as the scrutineer for the vote-taking at the EGM.
By order of the Board Sinopharm Group Co. Ltd. Jin Bin Chairman Shanghai, the PRC 19 December 2025 As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.
-3 -
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Sinopharm Group Co. Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVES | 0.19% | 1,262,400 | $ 2.728M | Nov 16, 2026 |
| DFSE | 0.11% | 307,600 | $ 656.399K | Nov 12, 2026 |
| AVEM | 0.08% | 10,106,800 | $ 21.84M | Nov 16, 2026 |
| AVSE | 0.06% | 62,400 | $ 134.84K | Nov 16, 2026 |
| DFEV | 0.05% | 566,400 | $ 1.209M | Nov 12, 2026 |
| DFEM | 0.05% | 2,129,600 | $ 4.544M | Nov 12, 2026 |
| DFAE | 0.03% | 1,391,600 | $ 2.97M | Nov 12, 2026 |
| DFAX | 0.02% | 884,000 | $ 1.886M | Nov 12, 2026 |